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Abstract
Opiate addiction is a chronic disorder with high rates of relapse. The failure to maintain
sobriety after prolonged abstinence is believed to be due in part to the persistence of potent
memories associated with the drug-taking experience. Activation of these memories by reexposure to drug-related cues can trigger craving in many individuals. Thus, understanding
the neurobiological processes underlying the formation of these memories may provide
insight into the persistence of addiction. The mammalian basolateral amygdala (BLA) and
medial prefrontal cortex (mPFC) comprise a functionally interconnected circuit that is critical
for processing opiate-related associative memories. There is some evidence that chronic
opiate exposure results in alterations to the function of dopamine (DA) D1 and D2 receptors
and their intracellular targets within the BLA, but critical questions remain in regards to these
effects within the BLA-mPFC circuit. For instance, opiate-induced alterations to intra-mPFC
DA signaling in the context of associative opiate memories has not yet been explored.
Furthermore, the role of the DA D3 receptor has not yet been investigated. Finally, there is
little understanding of the temporal dynamics underlying these changes in DAergic signaling.
Using behavioural models of associative memory formation (conditioned place preference
and conditioned place aversion) paired with analyses of protein expression, we further
characterized how chronic opiate exposure results in neuroplastic changes to DA receptor
expression and signaling in the BLA-mPFC pathway. Here, we report that chronic opiate
exposure results in a series of alterations to D1, D2 and D3 signaling within the BLA-mPFC
circuit in the context of both opiate reward and withdrawal aversion memories. Specifically,
we highlighted the importance of D2 and CaMKIIα signaling within the mPFC, identified the
role of intra-BLA D3-Cdk5-calcineurin signaling in reward and aversion memory formation,
and temporally mapped opiate-induced alterations to intra-BLA memory molecules.
Together, these results provide a more complete understanding of how opiate exposure
profoundly alters DA signaling between the dependent and non-dependent states.
Interestingly, we found that many of the changes induced by chronic opiate exposure are not
only transient, but may be functionally reversible, thus providing an avenue for future
development of pharmacological interventions for opiate addiction.

Keywords
addiction, associative memory, aversion learning, basolateral amygdala, conditioned place
aversion, conditioned place preference, D1 receptor, D2 receptor, D3 receptor, dopamine,
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Chapter 1

1

General Introduction

2

1.1 INTRODUCTION TO OPIATE ADDICTION
1.1.1

Epidemiology
Opiate addiction is a serious and growing health crisis, due in large part to the

over-prescription of opiates for pain and other health problems (Rudd et al., 2016). As of
2010, an estimated 15.5 million people worldwide are dependent on opioid drugs
(Degenhardt et al., 2014). The picture in Canada is even more alarming. Canada leads the
world in prescription opiate consumption per-capita (Moore et al., 2017), and Ontario is
recognized world-wide as being in a prescription-opiate crisis (Gomes et al., 2011;
Lynas, 2013). Opiate overdoses have become the leading cause of death for Ontarians
aged 18-35 (Gomes et al., 2014).

1.1.2

Opiate Addiction

The opiate class of drugs can act on any of the body’s three major opiate receptor classes
in the central and peripheral nervous system: δ, κ, and µ. Opiates such as morphine,
heroin and synthetic opiate analogues, act preferentially on the  opiate receptor system.
Opiates can include extracts from the poppy seed (e.g. morphine) as well as semisynthetic (e.g. heroin) and synthetic (e.g. oxycodone, fentanyl) drugs.
Opiates are highly effective in treating chronic pain, but also possess high abuse and
addiction potential due to their ability to elicit intense feelings of pleasure or euphoria
(Fields and Margolis, 2015). Repeated use and abuse of opiates leads to neuroadaptations
that result in both physical and psychological dependence and, in turn, continued drug
use (Koob and Le Moal, 2001). Opiate dependence can increase the risk for other serious
health problems such as HIV/AIDS and hepatitis C as a result of injection drug use
(Nabipour et al., 2014). Those who abuse opiates are also more prone to social
marginalization (Raketic et al., 2013) and illegal activity, as users turn to whatever means
possible to obtain the drug (Fischer et al., 2005).
With repeated use, individuals can rapidly develop tolerance and require escalating doses
of the drug to experience the desired effects. This is accompanied by dependence, which
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is typically discovered in individuals after the cessation of drug use (Le Merrer et al.,
2009). The resulting withdrawal state is reflected by severe withdrawal symptoms, such
as nausea, pain, feelings of unease and drug craving (Koob, 2009).
The characteristics of the addictive process can be broadly divided into three stages:
binge/intoxication, withdrawal/negative affect, and preoccupation/anticipation (Koob and
Volkow, 2016). Perhaps most notably, addiction results in continued and compulsive
drug use despite negative social, economic and/or health consequences.

1.1.3

Treatment

There is no known cure for addiction (Kalivas and Volkow, 2005). There are, however,
many pharmacological treatments available to help minimize withdrawal symptoms and
ease the transition away from opiate dependence.
Opiate agonist treatments are perhaps the most common of these medications, and
include methadone and buprenorphine. Opiate agonist treatments are widely regarded as
effective for reducing withdrawal symptoms, opioid craving, and criminal activity
associated with drug seeking (Zanis and Woody, 1998; Kleber, 2008; Huhn et al., 2014).
However, they are costly, carry abuse potential and are not completely effective in
preventing relapse (Mitchell et al., 2009; Cotton et al., 2017).

1.1.4

Relapse: A Moral Weakness?

Rates of relapse are enormously high for people that have abused opiates, regardless of
the length of time spent abstinent. Even following rehabilitation and detoxification,
relapse to heroin can be as high as 85% following successful completion of treatment
programs (Hunt et al., 1971). Anxiety, dysphoria and stress are common factors that can
result in drug craving and relapse to drug use. For some individuals, relapses can occur
years beyond the cessation of drug use and the experience of withdrawal (McLellan et al.,
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2000). As a result, scientists and clinicians have expressed the need for a different
approach to treating addiction (Fischer et al., 2016).
One particularly powerful trigger for craving is exposure to opiate-related stimuli. Due to
their highly rewarding nature, the use of opiate drugs results in the formation of potent,
euphoric memories of stimuli associated with the drug-taking experience. These can
range from paraphernalia to people, locations and even olfactory cues (Hone-Blanchet et
al., 2014). High rates of relapse, failed treatment programs and an inability for people to
“choose” to stop drug use have led to a strong perception of addiction as a moral failing
or personal weakness (Harding, 1986). However, researchers have uncovered a more
compelling explanation for the persistence of addiction, even in the most well-intentioned
individuals.

1.2 CONCEPTUALIZING ADDICTION: CLINICAL AND
NEUROBIOLOGICAL MODELS
1.2.1

Disease Model of Addiction

With the development of neuroscience research, theories behind the persistence of
addiction moved away from placing blame on maladaptive personality traits, and towards
viewing addiction as a brain disease with underlying physiological abnormalities
(Leshner, 1997; Wise, 2004; Hyman, 2005). There is a considerable body of research that
has investigated this hypothesis in an effort to uncover the precise mechanisms of the
brain disease model of addiction.
Evidence has emerged that the addicted and the non-addicted brain differ in specific,
measurable ways such as alterations to receptor availability, gene expression and
responses to environmental stimuli (Self, 2004; Thomas et al., 2008; Oever et al., 2012).
In response to these scientific advances, a variety of hypotheses have further been
proposed in an effort to explain the development and persistence of opiate addiction.
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1.2.2

The Dopamine Reward Hypothesis of Addiction

The dopamine (DA) reward hypothesis was developed by Roy Wise in the 1980s, and
posits that DA within the brain is critical for subjective pleasure gleaned from positive
rewards (Wise, 2008). The hypothesis is based on the assumption that behaviour can be
controlled by reward and punishment. Early support for a biological basis of this notion
came from studies that humans would both work for, and gain pleasure from, electrical
stimulation of targeted forebrain regions, among them the lateral hypothalamus (SemJacobsen, 1959; Heath, 1963). Wise and Stein (1969) shortly thereafter identified DA as
the neurotransmitter responsible for transmitting the reward signals that influence
behaviour.
The DA reward hypothesis states that DA release initiated by exposure to rewarding
stimuli is crucial for the habit-forming properties of addictive drugs (Wise and Bozarth,
1982). Wise proposes that users seek out drugs to experience a degree of pleasure (i.e. a
release of DA) far greater than what is provided by natural stimuli such as food.
Following the initial exposure, reward-related stimuli can then incite a motivational
drive, where users are driven to further seek out the rewarding stimulus. Repeated DArelease by subsequent exposures to the stimulus further “stamp-in” the motivational
importance of the stimulus (Wise, 2004). However, the eventual finding that aspects of
morphine and nicotine reward could be DA-independent suggested that the hypothesis
was an incomplete model for the development of opiate addiction.

1.2.3

The Opponent-Process Model of Addiction: Addiction as
Hedonic Allostasis

The opponent-process model of addiction places heavy weight on the role of emotional
states in the development of addiction. Drugs of abuse can elicit a range of emotions from
potent euphoria to overwhelming dysphoria. George Koob proposes that the experience
of such emotional extremes disrupts emotional homeostasis, and results in the emergence
of an allostatic state.
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Both positive reinforcement (i.e. euphoria experienced by drug taking) and negative
reinforcement (i.e. experience of withdrawal) are hypothesized to contribute to allostatic
changes to both stress and reward systems within the brain (Koob, 2015). As an
individual transitions from impulsive drug use to compulsive drug use, the motivation
underlying drug seeking and drug taking is proposed to be driven less by positive
reinforcement, and increasingly by negative reinforcement.
The mechanism underlying this transition is believed to be a decrease in the
responsiveness of the brain’s reward system and an overactivation of anti-reward systems
(Ahmed and Koob, 2005). The neurobiological underpinnings of this hypothesis have
been identified as multiple counter-adaptive opponent processes (Koob and Le Moal,
2001). The dysfunction of reward has been linked to the ventral striatum, and the
emergence of stress systems has been localized to the amygdala. The combination of
decreased reward transmission paired with activation of the stress systems is believed to
be a major motivation for the re-emergence of drug seeking and drug taking behaviours
(Koob et al., 2004).

1.2.4

The Incentive Salience Model of Addiction

The incentive salience model of addiction posits that addiction is a result of an overattribution of the incentive salience of drugs resulting from drug-induced sensitization of
reward pathways.
In vulnerable individuals, repeated exposure to potentially addictive drugs can alter the
brain circuits that regulate the attribution of incentive salience to stimuli. As a result,
these circuits are rendered hypersensitive (Robinson and Berridge, 1993). This
hypersensitivity results in pathologically high levels of incentive salience being attributed
to the drug and their related cues (Robinson and Berridge, 2008).
In this model, the incentive sensitization can result in the persistence of desire for drugs
for years, a phenomenon which can persist even long after drug use has ceased. Both
unconscious desire for the drug and the conscious cravings are proposed to be
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manifestations of sensitized incentive salience. The neurobiological underpinnings of the
incentive salience model are situated within the mesocorticolimbic system (Berridge and
Valenstein, 1991).

1.2.5

Addiction as a Disorder of Learning and Memory

Disorders of memory are most commonly associated with those of memory loss, with
Alzheimer’s disease and other dementias representing the most salient examples. There
is, however, the possibility that memory may also be disordered by forming associations
that are too powerful, leaving individuals unable to forget certain memories. This can be
particularly disruptive in people who have formed associations that are maladaptive
(Hyman, 2005).
Opiate abuse can result in the formation of euphoric memories related to the drug-taking
experience. These highly potent memories are easily triggered by drug-related cues, are
able to produce strong subjective craving and can therefore be a major factor in driving
drug use. More specifically, the drug-taking experience can become motivationally
significant as a result of association with environmental cues via Pavlovian conditioning
(Gawin and Kleber, 1986; O’Brien et al., 1998). To users, drug-related cues possess the
ability to predict drug availability, trigger memories of the drug’s effects, generate
cravings (even after long periods of abstinence) and prompt drug-seeking behaviours
(Wikler, 1984; Grant et al., 1996; Childress and Mozley, 1999; Garavan et al., 2000;
Robbins and Everitt, 2002; Volkow et al., 2012). These cues can include both internal
(i.e. somatic sensations, including withdrawal) and external (i.e. environments, drug
paraphernalia and even people) stimuli associated with drug use (Hyman et al., 2006).
This idea has been corroborated by evidence that addicts tend to relapse in settings
associated with prior drug use, and have an easier time remaining abstinent in contexts
without a previous association with drug use (Lüscher, 2016). For instance, heroinaddicted Vietnam veterans had much higher success rates staying abstinent upon return to
the US as compared to local addicts (see Robins, 1993 for review).
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Research has suggested that just as drugs of abuse act on normal mechanisms of reward
processing, they also potently activate normal mechanisms of reward learning (Hyman et
al., 2006). It is therefore possible that just as opiates over-activate reward systems, they
also trigger the formation of highly potent reward memories that are stronger than those
formed for natural reinforcers (Robbins and Everitt, 1999; Everitt and Robbins, 2005;
Belin et al., 2013).
In their model of the development of addiction, Koob and Le Moal (2001) emphasize the
importance of learning and reinforcement in the transition from voluntary drug use to loss
of control and compulsive use (i.e. addiction). They describe addiction as an endpoint of
the transition from occasional voluntary use to the loss of control, and underscore drug
seeking as being representative of a state where addicts are driven by the activation of
drug-related memories by drug cues in a stimulus-response manner (Robbins and Everitt,
1999; Everitt and Robbins, 2005; Belin et al., 2013; Everitt, 2014).
Specifically, they highlight the ability of even initial drug seeking and self-administration
to drive incentive learning, and increase the desire for reward derived from external
stimuli (Robinson and Berridge, 2008; Berridge et al., 2009). From there, controlled and,
eventually habitual, drug use provides the opportunity for conditioned reinforcement
between drug-induced euphoria and drug-related stimuli. Heavy intoxication and binges
are proposed as mechanisms for further disrupting cognition, and eventually lead to the
failure of executive control and, ultimately, addiction. Opiate drugs, given their
particularly powerful ability to elicit euphoria, can result in an especially rapid
progression to the addictive state.

1.2.6

Testing Reward Learning in Animal Models

In order to test the validity of this hypothesis of addiction and understand its cellular and
molecular mechanisms, the use of animal models of addiction is vital. Two of the most
common preclinical ways to probe the formation and expression of associative drug
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memories in animal models are the conditioned place preference (CPP) and conditioned
place aversion (CPA) paradigms.
CPP involves training an animal in either a drug- or a vehicle- paired environment, then
testing whether the animal forms a preference for the drug-paired environment, as
demonstrated by the expression of drug-seeking behaviour when placed into the drugpaired environment in a drug-free state (Bechara and van der Kooy, 1989; Nader and van
der Kooy, 1997; Bechara et al., 1998). The CPP paradigm is the most popular tool for
assessing the learning processes involved in the development and expression of contextdrug associations (Bardo and Bevins, 2000), and is based on the assumption that animals
will spend more time in an environment where they previously received drugs than in one
where they received only a vehicle solution (Bardo and Bevins, 2000; Hyman et al.,
2006).
Conversely, CPA measures the negative affective properties of subjective opiate
withdrawal (Stinus et al., 2000; Azar et al., 2003; Wang et al., 2012). Here, animals are
trained in one environment in a state of withdrawal. Upon testing, animals will typically
spend less time in the withdrawal environment than an environment with no previous
association.
Indeed, preclinical evidence has found that chronic exposure to drugs of abuse results in
alterations to the neural mechanisms underlying both CPP and CPA processing (reviewed
in Tzschentke, 2007; see section 1.6). One of the major areas of research surrounding
how drug addiction alters learning and memory processing involves studies of DAergic
function (Berke and Hyman, 2000). Given its role in the processing of reward,
motivation, and cognition, the mesocorticolimbic DA system has thus become a major
target of addiction research.
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1.3 THE NEUROANATOMICAL BASIS OF OPIATE
ADDICTION: THE MESOCORTICOLIMBIC PATHWAY
All drugs of abuse act on the mesocorticolimbic pathway in some way. The
mesocorticolimbic system is a major DA circuit that consists of a number of
interconnected regions (See Fig 1.1) Together, this system processes subjective pleasure,
motivation, reward learning and associated behavioural responses. Unsurprisingly,
dysfunction of the mesocorticolimbic system has been found both in addicted humans
and in preclinical models of addiction.
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Figure 1.1 The mesocorticolimbic system
This schematic represents a theoretical framework for how opiate reward is processed in
the mesocorticolimbic system. By acting on µ opioid receptors in the VTA, opiate drugs
remove GABAergic inhibition, and allow for DA signals to the BLA. Here, integration
with sensory regions allows for the processing of first-order associative memories. Over
time, associative memories transition to the mPFC for further processing and storage, and
alterations are made within the BLA-mPFC pathway. Recall of opiate memories may be
triggered by the exposure to drug-related cues, and the resulting behavioural output is
processed in the NAc.
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1.3.1

Ventral Tegmental Area

The ventral tegmental area (VTA) is the primary site of opiate reward processing (Breiter
et al., 1997). Direct infusion of morphine into the VTA promotes drug-seeking
behaviours, whereas infusion into other areas of the mesocorticolimbic system fail to
produce such effects (Olmstead and Franklin, 1997). Opiate class drugs act on µ opioid
receptors within the VTA to disinhibit GABAergic inputs to DA interneurons, thus
allowing for the processing of reward (Johnson and North, 1992; Klitenick et al., 1992).
Activation of µ opioid receptors within the VTA also increases DA transmission to
connected areas, increasing DA concentration (De Vries and Shippenberg, 2002; Adinoff,
2004; Ford et al., 2006). There is ample evidence that activation of the VTA by drugs of
abuse results in this increase in DA release in the amygdala, hippocampus, prefrontal
cortex and nucleus accumbens.

1.3.2

Nucleus Accumbens

The nucleus accumbens (NAc) integrates signals from connected mesocorticolimbic
areas into signals that drive behavioural responses to stimuli, representing the “limbicmotor interface” (Ambroggi et al., 2009). In the context of drug-related stimuli, the shell
division of the NAc facilitates drug-seeking behaviour following the activation of an
associative drug memory (Bassareo et al., 2002). Importantly, DAergic projections from the
VTA to the NAc are considered to be the chief pathway for processing the acute rewarding
effects of opiate drugs (Wise, 1989; Nader and van der Kooy, 1997).

1.3.3

Basolateral Amygdala

The basolateral nucleus of the amygdala (BLA) is involved in both appetitive and
aversive Pavlovian conditioning (Baxter and Murray, 2002). The BLA receives a wide
variety of sensory inputs from the thalamus, frontal cortex, and, relevant to opiate reward
processing, the VTA (Pitkänen et al., 2000). In turn, the BLA projects to the PFC, NAc
and hippocampus, among others.
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The BLA receives direct DAergic inputs from the VTA (Ford et al., 2006), however it is
not involved in the direct perception of opiate euphoria itself (Olmstead and Franklin,
1997). Instead, the BLA acts as a hub to integrate VTA DAergic input with sensory and
associative information (Grace and Rosenkranz, 2002; Rosenkranz and Grace, 2003).
Indeed, lesions of the BLA will impair heroin-seeking behaviour, and pharmacological
inhibition of BLA signaling prevents the reinstatement of cue-induced heroin seeking
(Alderson et al., 2001; Fuchs and See, 2002).
In addition to reward memory processing, the BLA also processes aversion memories
related to opiate withdrawal. BLA activation, as measured by c-fos expression, has been
found to increase in response to associative memory processing. This is contrasted by
adjacent neurons in the central amygdala being activated only in response to acute opiate
withdrawal, rather than memory processing (Frenois, 2005).

1.3.4

Medial Prefrontal Cortex

The medial prefrontal cortex (mPFC) regulates cognition and, via reciprocal connections
with the BLA, emotion (Little and Carter, 2013). Specifically, neuronal populations
within the mPFC encode opiate-related memories, as demonstrated by increased firing in
response to the recall of such memories (Sun et al., 2011).
Neuroimaging studies have suggested that dysfunctional activation of the mPFC in
humans results in impaired executive function and increased impulsivity. These results
have further been correlated with the compulsive drug-seeking and inability to suppress
maladaptive behaviours seen in opiate addicts (Volkow and Fowler, 2000; Goldstein and
Volkow, 2002; Kaufman et al., 2003; Paulus et al., 2005).
Both preclinical and clinical studies have implicated the mPFC in the expression of cueinduced associative opiate memory activation. This memory activation has been linked to
opiate seeking and consumption in a variety of human imaging and animal studies
(Daglish and Weinstein, 2001; Volkow et al., 2004; Langleben et al., 2008).
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Blocking DA transmission within the mesolimbic DA system, either via lesion or
application of DA antagonists, has been demonstrated to inhibit the development of a
preference to environments associated with opiate drugs (Wise, 1989; Wise and Rompre,
1989). Further behavioural studies have corroborated this link, as well. Sun et al. (2011)
found that neurons in the mPFC, specifically within the prelimbic cortex, increased firing
and bursting activity in response to re-exposure to environmental cues that had been
previously paired with morphine-induced reward. Chang et al. (1997) also demonstrated
that neuronal response patterns within the mPFC varied depending on the phase of
opiate-related drug seeking behaviour. The involvement of the mPFC in the processing of
opiate related memories is also evidenced at the genetic level, influencing immediate
early gene markers. Cue-induced reinstatement of heroin seeking has been found to
increase both c-fos and zif268 in prelimbic neurons, even up to 3 weeks following heroin
extinction (Shalev et al., 2003; Schmidt et al., 2005)
Most importantly, bidirectional connections between the BLA and mPFC, particularly
when associated with DAergic signaling within the mesocorticolimbic system, control the
acquisition and processing of opiate associative memories (Gholizadeh et al., 2013).

1.4 THE BLA-mPFC PATHWAY PROCESSES OPIATERELATED ASSOCIATIVE MEMORIES
Although a great deal of research has focused on how the mammalian brain processes
reward, the neural circuitry of reward processing is distinct from the substrates that
encode environmental and associative drug-related cues. Understanding this distinction
allows for a more direct examination of the phenomena that contribute to the persistence
of addictions, even after long periods of abstinence. The BLA-mPFC pathway is largely
responsible for the higher-order processes involved in the formation of associative opiate
memories, and both of these regions are believed to play critical roles in reward valuation
and the acquisition of reward memories (Everitt, 2003; Kalivas et al., 2005).
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The functional connection between the BLA and mPFC in heroin-dependent individuals
is not well studied, but evidence of disordered resting state activity has been found
(Zhang et al., 2011, 2015). Xie and colleagues (2011) have also reported a correlation
between impulsivity in heroin-abstinent addicts and hyperactivity in the amygdala-frontal
cortical circuit.
In animal models, connectivity between the BLA and mPFC has been implicated in the
acquisition, consolidation and expression of associative opiate reward memories. For
example, pharmacological inactivation of the BLA has been found to block the
potentiation of opiate reward memory formation that can be induced via NMDA receptor
antagonism within the PFC (Bishop et al., 2011). Inputs from the BLA are also necessary
for consolidation of opiate reward memory within the mPFC. Gholizadeh and colleagues
(2013) found that inhibition of protein synthesis within the BLA prevents the
consolidation of opiate memories in the mPFC when administered up to 3 hours
following behavioural conditioning. However, the consolidation of opiate reward
memories transfers to a mPFC-dependent mechanism between 6 and 12 hours following
conditioning, indicating that the consolidation of opiate reward memories follows a
temporal gradient between BLA and mPFC in the early- and late-stages following
behavioural conditioning, respectively. The BLA also impacts the role of the mPFC in
later consolidation and recall of opiate associative reward memories. For instance, Sun
and Laviolette (2012) found that inactivation of the BLA during reward learning results
in later facilitated extinction of both opiate reward and aversion memories, as reflected by
neuronal activity within the PFC.

1.5 OPIATE REWARD MEMORY LEARNING:
INVOLVEMENT OF DOPAMINE
The rewarding effects of drugs of abuse are believed to result from an increase in DA
concentration within the mesolimbic system (Di Chiara and Imperato, 1988). For
instance, morphine, methadone, ethanol, nicotine, amphetamine and cocaine all increase
DA within the mesocorticolimbic system (Di Chiara and Imperato, 1988). Some
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researchers even posit that dysfunctional DA signaling can predispose individuals to drug
use and abuse in an effort to overcome their natural DA deficiency (Blum et al., 2011,
2012a, 2012b).
DA was once believed to directly represent the expression of pleasure within the brain,
but evidence that animals can demonstrate DA-independent hedonic responses has
changed this viewpoint. Animals have expressed preference for drugs in studies that
blocked DA pharmacologically, via lesioning, or by genetic inactivation of the ratelimiting enzyme in DA synthesis, tyrosine hydroxylase (Berridge and Robinson, 1998;
Cannon and Palmiter, 2003; Robinson et al., 2005). Thus, a more complex role for DA
than representing a direct reward signal was proposed. Beyond the processing of acute
reward, the mesocorticolimbic pathway is considered the primary circuit for encoding
drug-related associative reward or withdrawal aversion memories (Wise, 1989; Koob and
Volkow, 2010). DA signaling is believed to play a central role in reward learning by
assigning incentive salience to reward-related cues, thus allowing for those cues to trigger
a “wanting” state with future exposure (Schultz et al., 1997; Berridge and Robinson,
1998; Schultz, 2006).
Extending this notion, researchers developed the hypothesis that DA encodes the
prediction of reward, rather than reward itself (Ikemoto, 2010). Specifically, DA is
believed to encode the history of reward, and this information allows individuals to form
predictions and act in a way that maximizes the receipt of a reward (Sutton and Barto,
1999; Montague et al., 2004). Schultz and colleagues tested this hypothesis in awake
monkeys during a classical conditioning task. They found that the delivery of an
unexpected reward resulted in a phasic increase in DA firing within the VTA. Once the
conditioned stimulus was acquired, reward delivery no longer increased firing of DAergic
neurons (Schultz et al., 1993, 1997; Hollerman and Schultz, 1998; Schultz, 1998, 2006).
Bayer & Glimcher (2005) extended this idea further and found that the firing of midbrain
DA neurons fired most reliably to rewards that were “better than expected”. Interestingly,
the application of DA’s role in reward prediction in computational models has provided
evidence that due to their ability to potently increase synaptic DA, drugs of addiction will
consistently produce a “better than expected” signal. Thus, future behaviour becomes
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geared towards the acquisition of drugs over natural stimuli that cannot produce as potent
a reward signal (Montague et al., 2004; Redish, 2004). Given its role in reward
processing, the study of DAergic signaling is therefore a promising avenue for
understanding how drugs of abuse exert their effects on the addicted brain.

1.5.1

Dopamine Receptor Signaling

DA receptors are G-protein-coupled receptors that fall into two categories, the D1 and D2
receptor families, based on their ability to modulate adenylyl cyclase (AC) and cyclic
AMP (cAMP) activity (Kebabian and Calne, 1979; Andersen et al., 1990; Sibley and
Monsma, 1992). Further genetic analyses have revealed a total of five DA receptors,
which are further classified by their structural and pharmacological properties.
Specifically, the D1 family (D1, D5) and the D2 family (D2, D3, D4) were defined
(Andersen et al., 1990; Tiberi et al., 1991; Sibley and Monsma, 1992; Sokoloff et al.,
1992). In addition to their differing action on AC, DA receptors demonstrate differences
in their distribution, sensitivity to DA, and their intracellular signaling targets. These
distinctions will be discussed below, with a particular focus on DA D1, D2 and D3
receptors for their role in reward and reinforcement processing.

1.5.2

D1 Receptors

The D1 family of receptors activate the Gαs/olf family of G proteins, and stimulate cAMP
production via AC. They are located exclusively on post-synaptic DA cells, including
striatal GABAergic medium spiny neurons (MSNs) (Beaulieu and Gainetdinov, 2011).
D1 receptors are highly expressed in mesocorticolimbic regions (Missale et al., 1998;
Vallone et al., 2000; Beaulieu and Gainetdinov, 2011). For instance, the BLA specifically
sends projections to MSNs that express D1 receptors (Floresco et al., 2001; Wall et al.,
2013; Wassum and Izquierdo, 2015).
The D1 receptor is critical for learning and memory (Goldman-Rakic et al., 2004). For
instance, behavioural conditioning has been reported to require phasic DA activation via
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D1 receptors (Kauer and Malenka, 2007; Zweifel et al., 2009). The D1 receptor also
plays a role in drug reward processing. For example, D1 knockouts will not selfadminister cocaine (Caine et al., 2007). Increased D1 signaling is associated with the
emergence of a sensitized response to drug administration (Bertran-Gonzalez et al.,
2008). Furthermore, D1 has been implicated in conditioning for drug reward (Volkow et
al., 2012).
With respect to intracellular signaling, D1 receptors regulate a variety of pathways, one
of which is ERK1/2. Interestingly, activation of D1, but not D2, has been reported to
increase the activity of ERK1/2 in the NAc and mPFC (Xue et al., 2015). ERK1/2 has
also been linked to D1 signaling in reward conditioning studies. Kirschmann et al. (2014)
found that a D1-NMDA mechanism was necessary for conditioned reward stimuli to
activate ERK1/2 signaling in the NAc. Furthermore, reports of psychostimulant-induced
ERK1/2 activation has been reported to occur exclusively in striatal neurons expressing
D1 (Bertran-Gonzalez et al., 2008). Finally, both intra-BLA D1 and ERK1/2 have been
implicated in the formation of opiate reward memory. Following chronic exposure to
opiates, however, the expression of ERK1/2 within the BLA becomes downregulated,
and opiate reward memory formation becomes independent of a D1-ERK1/2 mechanism
(Lintas et al., 2011; Lyons et al., 2013).

1.5.3

D2 Receptors

Unlike D1 receptors, the D2 family of receptors are coupled to Gαi/o G-proteins, allowing
them to inhibit the production of cAMP (Beaulieu and Gainetdinov, 2011). D2 receptors
can be found either pre- or post-synaptically, making their function within the brain more
dynamic than that of D1 (Sokoloff et al., 2006; Rondou et al., 2010; Beaulieu and
Gainetdinov, 2011). D2 receptors are found predominantly in the striatum and NAc, but
are also present in the amygdala and other cortical regions (Missale et al., 1998; Vallone
et al., 2000; Beaulieu and Gainetdinov, 2011).
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Like the D1 receptor, D2 is involved in learning and memory mechanisms (Xu et al.,
2009). D2 has a higher affinity for DA than D1, making it more likely to be easily
activated following drug-induced DA release and thus influence reward processing
(Durieux et al., 2009).
In the context of drug addiction, dysfunction of the D2 receptor has been linked with
impulsivity, and may be able to predict later development of addiction (Trifilieff and
Martinez, 2014). Decreases in D2 signaling have been associated with a preference for
immediate reward and compulsive intake (Perez et al., 2011; Trifilieff and Martinez,
2014). Conversely, increased D2 activation is linked with a willingness to exert greater
effort in order to achieve a reward (Martinez et al., 2012; Trifilieff and Martinez, 2014).
One of the known intracellular signaling functions of the D2 receptor is to regulate
calcium signaling. Neuronal calcium sensor-1, for instance, is involved in the
desensitization of D2 receptors (Kabbani et al., 2002; Woll et al., 2011). Furthermore,
CaMKII has been reported to directly modulate D2R function (Liu et al., 2009), and its
activation has been linked to the reinstatement of morphine-seeking behaviors (Liu et al.,
2012a, 2012b).
Finally, intra-BLA CaMKIIα has demonstrated a dramatic downregulation following
chronic exposure to heroin. Interestingly, this decrease was associated with the
emergence of a D2/CaMKIIα-sensitive substrate underlying the acquisition of opiate
reward memories (Lintas et al., 2011; Lyons et al., 2013).

1.5.4

D3 Receptors

The D3 receptor is a member of the D2 family, and has a unique distribution pattern in
the central nervous system. It is expressed mostly in limbic regions such as the NAc shell
region (Sokoloff et al., 1992; Missale et al., 1998; Beaulieu and Gainetdinov, 2011). The
localization of the D3R within the limbic system makes it a promising target for addiction
research (Goodman, 2008).

20

Reports of D3 receptor function highlight its critical role in drug-induced reward learning
(Di Chiara and Imperato, 1988; Nestler, 2005; Stuber et al., 2005; Hyman et al., 2006;
Schultz, 2010). As a result, the D3 receptor has become a major target of
pharmacological therapies aimed at treating addictive disorders (Parsons et al., 1996;
Pilla et al., 1999; Heidbreder et al., 2005; Micheli and Heidbreder, 2008; Heidbreder and
Newman, 2010).
Intracellular targets of the D3 receptor include cyclin-dependent kinase 5 (Cdk5) and
calcineurin, among others that overlap with intracellular D2 targets (Chergui et al., 2004;
Chen et al., 2009; Liu et al., 2009; Avalos-Fuentes et al., 2013). Intracellular action
resulting from D3 signaling has been previously linked to synaptic plasticity mechanisms
and memory formation for conditioned reward (Mansuy et al., 1998; Biala et al., 2005;
Baumgärtel and Mansuy, 2012; Lyons et al., 2013).

1.6 EVIDENCE OF A MOLECULAR SWITCHING
PHENOMENON IN THE OPIATE ADDICTED BRAIN
The notion that opiate exposure results in long-term changes to the biochemical signaling
properties of the mammalian brain has been evaluated for decades. One of the earliest
examinations of this hypothesis was performed by Nestler and Aghajanian (1997). They
reported that acute opiate exposure inhibits cAMP-dependent protein phosphorylation
within the locus coeruleus. With chronic opiate administration, this inhibition recovered
to baseline level, but then rebounded to much higher than normal levels in the presence of
an opioid receptor antagonist, thereafter remaining elevated.
More recently, it has become increasingly evident that prior history of opiate exposure
must be factored into studies of the neural mechanisms underlying opiate processing.
Opiate use in particular over other drugs of abuse can rapidly lead to dependence and
withdrawal, even after a single exposure (Larcher et al., 1998; Kawasaki et al., 2011;
Rothwell et al., 2012).

21

There is further evidence that previous history of opiate exposure can alter future
processing of opiate reward following an opiate-induced “switch” in reward processing
substrates. Bechara et al. (reviewed in 1998) pioneered research into the opiate switch
phenomenon. Their work uncovered two, distinct motivational pathways responsible for
processing opiate reward as a function of opiate exposure within the pedunculopontine
tegmental nucleus (PPT). They found that lesions of the PPT blocked the acquisition of a
morphine CPP only in rats with no previous exposure to opiates. Animals that were
opiate-dependent and in a state of withdrawal, however, were still able to express a CPP
for a morphine environment following PPT lesions. This switch between opiate naïve and
dependent/withdrawn states was attributed to a functional dissociation within the VTA.
Specifically, processing of morphine reward within the VTA was found to rely on a DAindependent PPT mechanism in the opiate naïve state, but opiate dependence and
withdrawal resulted in a transition to a DA-dependent system (Nader and van der Kooy,
1997; Bechara et al., 1998; Laviolette et al., 2002).
Further research into the opiate exposure state switching mechanism uncovered the role
of GABAA receptors within the VTA. Blockade of GABAA within the VTA of opiate
naïve rats resulted in the disinhibition of DA-independent reward signaling pathways via
the PPT (Laviolette and van der Kooy, 2004). In opiate-dependent rats in a state of
withdrawal, however, intra-VTA GABAA receptors mediated an excitatory signal, and
activated a DA-dependent reward signal via the mesolimbic DA circuit (Laviolette and
van der Kooy, 2003, 2004; Laviolette et al., 2004).
With a clear foundation for how opiate exposure can result in a functional switch in the
brain’s processing of the primary rewarding effects of opiates, the question remained how
opiate exposure may influence higher-order processing of opiate reward. For instance,
does opiate exposure also result in a similar functional shift in how opiate-related
memories are formed, and could such a switch be involved in the formation of the highly
potent drug-related memories that are evident in addicted individuals? Given its role in
the processing of opiate-related memories, the BLA was a prime candidate to seek further
evidence of the opiate-induced molecular switching mechanism.
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With the direct microinfusion of D1 and D2-specific antagonists into the rat brain, Lintas
et al. (2011) found that intra-BLA DA receptors mediate the formation of opiate reward
CPP as a function of opiate exposure. In animals with no prior exposure to opiates, intraBLA D1 antagonism blocked the formation of a morphine CPP, but not in opiatedependent/withdrawn animals. Antagonism of the intra-BLA D2 receptor, however,
successfully blocked the formation of a morphine CPP in opiate dependent animals, but
not opiate naïve animals.
To understand the molecular underpinnings of this double-dissociation of DA receptor
function in the BLA, targets of the intracellular D1 and D2 receptors were probed in a
similar manner. Lyons et al. (2013) tested the involvement of ERK1/2 in D1-dependent
opiate reward memory formation and CaMKIIα in D2-dependent memory formation.
They found that intra-BLA inhibition of ERK1/2 blocked the acquisition of a morphine
CPP memory in opiate naïve animals, but not in opiate-dependent animals. In contrast,
intra-BLA CaMKIIα antagonism prevented the formation of a morphine CPP in opiatedependent/withdrawn animals, but not opiate naïve animals. Furthermore, the ability for
D1 or D2 activation within the BLA to potentiate the salience of opiate reward was found
to rely on intra-BLA ERK1/2 and CaMKIIα signaling, respectively. Lyons et al. (2013)
further explored how the expression of ERK1/2 and CaMKIIα may be altered by chronic
heroin exposure, and found dramatic downregulations of CaMKIIα and a significant
decrease in the expression of ERK1/2. Together, these results suggested that chronic
opiate exposure leads to changes in the expression of intracellular DA signaling targets
that result in an opiate exposure state-dependent switch in the behavioural significance of
these signaling cascades in the formation of associative opiate reward memories.

1.7 SUMMARY AND RATIONALE
Long-term addiction is due in part to the persistence of opiate associative memories for
reward and aversion. While the above discussion has pointed out existing knowledge
pertaining to the neurobiological mechanisms by which opiates produce their rewarding
and addictive properties, much less is understood concerning how brain mechanisms
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responsible for opiate-related associative memories may contribute to the intractability of
opiate addiction. In conjunction with the formation of maladaptive memory formation,
opiate use results in physiological adaptations to create dependence and addiction,
specifically within the BLA-mPFC pathway of the mesocorticolimbic system.
Understanding acute vs. long-term opiate-induced changes to DA D1, D2 and D3
receptors and their downstream molecular memory signaling pathways within the BLAmPFC circuitry will help us to uncover the neurophysiological underpinnings involved in
the acquisition and persistence of opiate associative memories. Ultimately, this will
provide the preclinical research needed to understand, and hopefully treat, long-term
opiate addiction by revealing novel pharmacotherapeutic targets aimed at disrupting,
preventing and/or reversing neuropathological brain adaptations linked to the persistence
of opiate-related addiction memories.

1.7.1

General Hypothesis

My overarching hypothesis is that chronic heroin exposure results in a series of
alterations to both the function and expression of DA D1, D2 and D3 receptors and their
associated intracellular signaling targets within the BLA-mPFC pathway, with functional
consequences for reward and aversive associative drug memory formation during distinct
phases of the opiate addiction process. My thesis addresses this general hypothesis with
the following three specific research aims:

1. Investigate opiate exposure state-dependent alterations to D1 and D2 signaling
mechanisms within the BLA-mPFC circuit in the context of opiate reward
memory formation using a combination of conditioned place preference
behavioural analyses and molecular analyses of downstream molecular memory
signaling pathways involving the ERK 1/2 and CaMKIIα protein expression
patterns in the BLA-mPFC circuit.
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2. Investigate the specific role of D3 receptor signaling and its associated
downstream molecular signaling pathways within the basolateral amygdala in the
context of opiate reward and withdrawal aversion memory acquisition as a
function of opiate exposure state.

3. Explore the short vs. long-term temporal dynamics of how specific memory
signaling molecules involved in associative drug memory formation in the BLA
are altered following chronic heroin exposure, dependence and withdrawal.
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2

Opiate Exposure State Controls a D2-CaMKIIαDependent Memory Switch in the Amygdala-Prefrontal
Cortical Circuit

Adapted from Neuropsychopharmacology. 2016 Feb;41(3):847-57.
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2.1 INTRODUCTION
The mammalian basolateral amygdala (BLA) and medial prefrontal cortex (mPFC) form
a functionally interconnected circuit that is critical for the formation of memories linked
to the rewarding properties of opiates (Bishop et al, 2011; Sun and Laviolette, 2012; Sun
et al, 2011). Intra-BLA processing of opiate-related memories is mediated via dopamine
(DA) D1 receptor (D1R) and D2R signaling as a function of opiate exposure state.
Specifically, D1R transmission is required for acute opiate memory formation in the
previously drug-naïve state, whereas D2R signaling is necessary for opiate memory
formation during states of chronic opiate exposure and spontaneous withdrawal (Lintas et
al, 2011, 2012).
Extracellular signal-related kinase 1/2 (ERK1/2) and the Ca2+/calmodulin-dependent
protein kinase type II α isoform (CaMKIIα) are linked to DAergic activity and the
formation of drug-related memories (Lyons et al, 2013). ERK signaling is associated with
opiate reward and spontaneous withdrawal phenomena in mesocorticolimbic regions
(Morón et al, 2010; Valjent et al, 2004). Furthermore, chronic opiate exposure leads to
alterations in ERK signaling (Bilecki et al, 2005; Lyons et al, 2013). Activity of CaMKII
is involved in reinstatement of morphine-seeking behaviors (Liu et al, 2012a, b), and
modifications to CaMKII expression are linked to opiate exposure differentially between
acute and chronic treatments (Andersen et al, 2012; Lu et al, 2000; Lyons et al, 2013).
Although both molecules interact with D1R and D2R, ERK signaling is related more
closely to D1R-mediated effects (Fricks -Gleason and Marshall, 2011; Lai et al, 2008),
whereas CaMKII directly modulates D2R function (Liu et al, 2009). Opiate exposure not
only alters levels of ERK1/2 and CaMKII in the BLA, but ERK1/2 signaling is required
for acute opiate memory formation in rats with no history of opiate exposure. In contrast,
CaMKII-mediated signaling is necessary for memory formation following chronic opiate
exposure and spontaneous withdrawal (Lyons et al, 2013).
The mPFC is involved in processing opiate-related memories and in generating neuronal
responses to drug cues during relapse and drug seeking (Bossert et al, 2012; Doherty et
al, 2013; Lucas et al, 2012; Pelloux et al, 2013; Sun et al, 2011). The BLA-mPFC circuit
operates as an integrative, temporally mediated pathway during opiate-related associative
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memory processing (Bishop et al, 2011; Gholizadeh et al, 2013; Sun and Laviolette,
2012; Sun et al, 2011) and thus represents a crucial target for understanding the
processing of opiate reward memories (Cardinal et al, 2002). We hypothesized that
opiate-related molecular adaptations within the BLA-mPFC circuit may underlie the
transition between opiate-naïve vs chronically exposed states, during the formation of
opiate reward memories.
Using a combination of behavioral pharmacological and molecular analyses, we
investigated the role of intra-mPFC CaMKII, ERK1/2, and DAergic signaling during the
formation of opiate reward memories as a function of opiate exposure state. Remarkably,
we report that chronic opiate exposure and spontaneous withdrawal induces a functional
switch in the signaling pathways involved in the formation of opiate associative
memories within the mPFC that are functionally opposite to those observed in the BLA.
Thus, chronic opiate exposure and spontaneous withdrawal serves as a dissociative
boundary between distinct DAergic and CaMKII/ERK memory substrates within the
BLA-mPFC circuit.

2.2 MATERIALS AND METHODS
2.2.1

Surgical Procedures

All procedures were performed in accordance with the Canadian Council on Animal Care
and approved by the Western University Council on Animal Care. Male Sprague-Dawley
rats (350–400 g; Charles River) were anesthetized with ketamine/xylazine (80 mg and 6
mg/kg, respectively), given 1 mg/kg of meloxicam (non-steroidal anti-inflammatory
analgesic) and placed into a stereotaxic device. Stainless steel guide cannulae (22 gauge;
PlasticsOne) were bilaterally implanted into the brain regions of interest based on
anatomical boundaries defined by Paxinos and Watson (2005) as follows: mPFC (15°
angle), from bregma, anteroposterior (AP) − 2.9, mediolateral (ML) − 1.9, from the dural
surface, dorso-ventral (DV) − 3.0; BLA (no angle), from bregma, AP − 2.6, ML +5.0,
DV − 7.2. Rats in the mPFC-BLA disconnection groups received a single unilateral PFC
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cannulation and contralateral BLA cannulation. The hemispheres for unilateral
cannulations were counter-balanced within groups to control for laterality.

2.2.2

Drug Treatments

The selective CaMKII inhibitor autocamtide-2-related inhibitory peptide (AIP; Tocris
Bioscience), the D2/D3 antagonist eticlopride (eticlopride hydrochloride; Tocris
Bioscience), morphine (morphine hydrochloride, MacFarlane Smith), and heroin
(diacetyl-morphine, MacFarlane Smith) were dissolved in physiological saline, pH
adjusted to 7.4. The selective ERK1 inhibitor (PD334581; Tocris Bioscience) was
dissolved in a solution of 50% dimethyl sulfoxide (DMSO) and 50% physiological saline,
pH adjusted to 7.4, and prepared at room temperature. Microinjections into mPFC or
BLA (0.5 μl of volume per infusion) were delivered via plastic tubing connected to a 1 μl
Hamilton microsyringe over 1 min. Injectors were left in situ for an additional 1 min to
ensure diffusion from the injector tip. For all groups, microinfusions were performed
immediately before injections of morphine or saline (i.p.) and subsequent placement in
the conditioning environment. The dose of morphine used for conditioned place
preference (CPP; 5 mg/kg, i.p.) is a supra-reward threshold conditioning dose, and
produces robust behavioral CPP (Bishop et al, 2011; Lyons et al, 2013; Sun et al, 2011).

2.2.3

Chronic Opiate Exposure and Spontaneous Withdrawal

For rats in the chronic opiate exposure/spontaneous withdrawal condition, opiate
exposure and spontaneous withdrawal was induced as previously described (De Jaeger et
al, 2013; Lintas et al, 2011; Lyons et al, 2013). This regimen produces aversive
motivational effects (conditioned place aversion), which are qualitatively similar to those
produced following a 3-week morphine administration regimen (Nader et al, 1994;
Bechara et al, 1995; Laviolette and van der Kooy, 2004). Rats received daily
subcutaneous injections of 0.5 mg/kg heroin in their home cage starting 7 days before
behavioral conditioning, and the first conditioning session began 21 h following their last
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heroin injection. Maintenance doses of heroin were administered during the conditioning
phase 2.5 h following the end of each conditioning session, for a total of 15 injections
over the course of an experiment. Rats in the opiate-naïve condition were yoked to
chronic exposure/withdrawn animals with saline injections corresponding to heroin
injections.

2.2.4

Place Preference Conditioning

A fully counterbalanced, unbiased CPP paradigm was used as described previously
(Lintas et al, 2011; Lyons et al, 2013). Following surgical recovery, rats were preconditioned for 20 min in a motivationally neutral gray box and randomly assigned to an
experimental group. The 8-day conditioning procedure commenced the following day.
One conditioning environment was black with a Plexiglas floor that is wiped down with
0.25 ml of 2% acetic acid immediately before placing the rat into it. The alternating
environment was white with a wire mesh and woodchip floor, so the environments
differed in color, floor texture, and odor. These environments elicit no baseline
preference in rats, as reported previously (Laviolette and van der Kooy, 2003). Rats
received an equal number of morphine-paired and saline-paired conditioning sessions,
each 30 min in duration (i.e., four morphine environment pairings and four saline
environment pairings over the 8-day procedure). Testing occurred 3–5 days following the
final conditioning session in a drug-free state. The test environment contains both
conditioning environments separated by a narrow, neutral gray zone. At the start of the
10-min test session, rats are placed in the neutral zone, and time spent in each
environment is recorded and scored separately for each rat.

2.2.5

Histology

Following the completion of behavioral experiments, rats were deeply anesthetized with
euthanyl (sodium pentobarbital, 240 mg/kg, i.p.) and transcardially perfused with 0.9%
physiological saline, followed by 10% formalin. Once extracted, brains were refrigerated
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at 4°C in a 25% sucrose in formalin solution for a minimum of 48 h before sectioning at
40 μm. Brain slices were stained with Cresyl Violet for verification of BLA and mPFC
cannulae placements. Subjects with placements outside the anatomical boundaries (n = 25
out of total n = 152) as defined by Paxinos and Watson (2005) were excluded from
analysis.

2.2.6

Western Blot Procedure

Two groups of rats received 15 daily injections of physiological saline or heroin (0.5
mg/kg, s.c.), equivalent to those received during behavioral conditioning. Tissue was
extracted at 21 h following the final injection, and western blotting procedures were
performed as outlined in Lyons et al, 2013. Primary antibody dilutions were as follows:
α-tubulin (1 : 120 000; Sigma-Aldrich), phosphorylated ERK1/2 [T202/Y204] (pERK1/2;
1 : 2000; Cell Signaling Technology), total ERK1/2 (tERK1/2; 1 : 5000, Cell Signaling
Technology), phosphorylated CaMKIIα [T286] (pCaMKIIα; 1 : 10 000; Cell Signaling
Technology), total CaMKIIα (tCaMKIIα; 1 : 5000; Cell Signaling Technology), total
CaMKIIβ (1:100; Santa Cruz Biotechnology), Ca2+/calmodulin-dependent protein kinase
type IV (CaMKIV; 1:50 000; Sigma-Aldrich), calcineurin A (CnA; 1:100 000; SigmaAldrich), D1R (1:100; Santa Cruz Biotechnology), and D2R (1:100; Santa Cruz
Biotechnology). Secondary antibodies (Thermo Scientific) were all used at a dilution of
1:20 000. Blots were incubated in a TBS-T solution with either 5% non-fat dried milk
(Carnation) or 2.5% Bovine Serum Albumin Fraction V (Calbiochem) as recommended
by the manufacturer.

2.2.7

Data Analysis

CPP data were analyzed with two-way analysis of variance (ANOVA) with a betweensubjects factor of drug treatment, and a within-subjects factor of conditioning
environment. Post-hoc analyses were performed with Bonferroni corrections where
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appropriate. Densitometry values for western blots were obtained with Kodak digital
analysis software and analyzed with two-tailed t-tests.

2.3 RESULTS
2.3.1

Effects of Chronic Heroin Exposure and Spontaneous
Withdrawal on Calcium-Related Signaling Molecules in the
mPFC

Given previous findings showing a profound reduction in intra-BLA CaMKIIα
expression levels following chronic heroin exposure (Lyons et al, 2013), we first
examined the protein expression profile of the CaMKIIα isoform in the mPFC as a
function of opiate exposure state. Sample western blots presented in Figure 2.1a show
representative phosphorylated and total CaMKIIα levels in opiate-naïve vs chronic
exposure states. Rats chronically exposed to opiates and in spontaneous withdrawal at the
time of tissue processing (n = 8) showed no change in CaMKIIα phosphorylation levels
compared with vehicle-treated rats (Figure 2.1b; n = 8; t(14) = − 0.446, p = .662), but
displayed significantly increased total CaMKIIα expression (t(14) = − 3.152, p < .01). As a
result, the ratio of phosphorylated to total CaMKIIα was significantly decreased (Figure
2.1c; t(14) = 3.850, p < .01).
In order to investigate potential changes to other isoforms of CaMKII, we next tested the
CaMKIIβ isoform. A representative western blot is presented in Figure 2.1d. Analysis
revealed no significant increase in total CaMKIIβ expression in chronic opiate
exposure/withdrawn rats (n = 8) compared with vehicle controls (n = 8; t(14) = − 1.383, p
= .188; Figure 2.1e). To determine if opiate exposure targets CaMKIIα specifically or
Ca2+ (or Ca2+/calmodulin) more generally, we examined potential alterations to either
CaMKIV (Figure 2.1f and g) or calcineurin A (CnA) (Figure 2.1h and i). There was no
observed difference in the expression of CaMKIV or CnA between opiate-naïve vs
chronically exposed/withdrawn rats (t(13) = 0.153, p = .881; t(12) = − 0.075, p = .941,
respectively).
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Figure 2.1 Western blot analysis of calcium-related signaling molecules in the mPFC
Chronic heroin exposure results in a state-dependent alteration in the expression of
signaling molecules in the mPFC. (a) Representative western blot for phosphorylated and
total CaMKIIα expression. (b) Densitometry analysis revealed no significant changes to
phosphorylated CaMKIIα, but an increase in total CaMKIIα in opiate chronic
exposure/withdrawn tissue. (c) The ratio of phosphorylated to total CaMKIIα is
decreased in opiate chronic exposure/ withdrawn animals relative to saline-treated
animals. (d) Representative western blot for total CaMKIIβ. (e) Expression levels of
CaMKIIβ are unchanged following chronic heroin exposure. (f) Representative western
blot for total CaMKIV. (g) Levels of CaMKIV expression are not altered by chronic
heroin exposure. (h) Representative western blot for CnA. (i) Expression levels of CnA
are not changed by chronic heroin exposure (**p < 0.01; error bars represent SEM).

2.3.2

Histological Analysis for CPP Experiments

Histological analysis of intra-BLA and intra-mPFC cannula placements revealed
microinjector tips within the anatomical boundaries of BLA and mPFC as outlined in
Paxinos and Watson (2005). Figure 2 presents microphotographs and schematics of both
intra-BLA (Figure 2.2a and b) and intra-mPFC (Figure 2.2c and d) placements of
representative experimental groups. Histological analysis revealed intra-mPFC

52

placements to be localized to the pre-limbic (PLC) subregion of the mPFC. Rats found to
have placements outside the anatomical boundaries of the mPFC or BLA as defined by
Paxinos and Watson (2005) were excluded from analyses.

2.3.3

Opiate Exposure State Controls the Functional Role of IntramPFC CaMKII Signaling during Opiate Reward Memory
Formation

Given our observed changes in intra-mPFC CaMKIIα expression following chronic
opiate exposure and spontaneous withdrawal, we next evaluated the behavioral
significance of intra-mPFC CaMKII signaling across opiate exposure states. Here, we
used a previously tested behaviorally effective dose range of the highly selective CaMKII
inhibitor AIP (5–500 ng/0.5 μl) for bilateral intra-mPFC microinfusions (Lyons et al,
2013). First, using opiate-naïve experimental groups, intra-mPFC inhibition of CaMKII
dose-dependently blocked the acquisition of morphine (5 mg/kg; i.p.) CPP (Figure 2.2e).
Two-way ANOVA revealed a significant main effect of treatment (F(3, 25) = 10.93, p <
.01), main effect of environment (F(1, 26) = 14.55, p < .01) and treatment by environment
interaction (F(3, 22) = 3.05, p < .05). Post-hoc analyses revealed that whereas intra-mPFC
vehicle (n = 7) or the lowest dose of 5 ng AIP (n = 6) were ineffective at blocking
morphine CPP (p-values < .01), both 50 ng (n = 6) and 500 ng (n = 7) doses blocked the
formation of morphine CPP, with rats demonstrating no significant preference for
morphine vs saline-paired environments (p-values > .05).
We next examined the effects of intra-mPFC CaMKII inhibition on opiate reward
behaviors in chronically exposed/withdrawn experimental groups (see section 2.2). Using
the previously determined highest behaviorally effective dose of AIP (500 ng/0.5 μl; see
Figure 2.2e), we found that intra-mPFC blockade of CaMKII failed to block morphine
CPP. Although statistical analyses revealed a significant effect of group (F(1, 14) = 7.21, p
< .05) and conditioning environment (F(1, 15) = 68.44, p < .01), both the groups receiving
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Figure 2.2 Histology and analysis of CPP experiments evaluating the role of intramPFC and intra-BLA CaMKII activity across opiate exposure states
Intra-mPFC and intra-BLA CaMKII signaling is functionally controlled by opiate
exposure state. (a) Representative microphotograph of intra-BLA guide cannulae and
microinjection tip placement. (b) Schematic of bilateral intra-BLA placements. Open
triangles: 500 ng AIP in the opiate-naïve state; closed triangles 500 ng AIP in the chronic
exposure/ spontaneous withdrawal state. (c) Representative microphotograph of intramPFC guide cannulae and microinjection tip placement. (d) Schematic of bilateral intramPFC placements. Open circles: 500 ng AIP in the opiate-naïve state; closed circles: 1 μg
UO126 in the opiate chronic exposure/withdrawn state. (e) Intra-mPFC microinfusion of
AIP dose-dependently blocked the acquisition of a morphine (0.5 mg/kg) CPP in a range
from 5 ng to 500 ng in the opiate-naïve state. (f) Intra-mPFC microinfusion of 500 ng
AIP did not block the acquisition of a morphine CPP in the opiate chronic
exposure/withdrawn state. (g) In opposition to the mPFC, intra-BLA microinfusion of
500 ng AIP did not block the acquisition of a morphine CPP in rats trained in a
previously opiate-naïve state; (h) however, intra-BLA microinfusion of 500 ng AIP
blocked the acquisition of a morphine CPP in the opiate chronic exposure/withdrawn
state (**p < 0.01; error bars represent SEM).
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intra-mPFC AIP (n = 7) and vehicle (n = 8) demonstrated robust morphine CPP at testing
(Figure 2.2f; p-values < .01). In contrast to these findings in the mPFC, we have
previously reported that intra-BLA CaMKII activity is not required for the acquisition of
morphine CPP in the opiate-naïve state but, is necessary during states of chronic opiate
exposure/spontaneous withdrawal (Lyons et al, 2013). Thus, to confirm the role of intraBLA CaMKII signaling across opiate exposure states, we next examined the effects of
intra-BLA CaMKII inhibition on opiate reward memory acquisition. Consistent with
previous findings (Lyons et al, 2013), intra-BLA CaMKII inhibition in the opiate-naïve
state failed to block morphine CPP relative to vehicle controls. Two-way ANOVA
revealed a significant effect of conditioning environment (Figure 2.2g; F(1, 12) = 86.59, p
< .01), and both the vehicle (n = 7) and 500 ng AIP (n = 5) groups showed significant
place preference for the morphine-paired environment following behavioral conditioning
(p-values < .01). Inhibition of intra-BLA CaMKII, however, blocked the acquisition of
morphine CPP in chronically exposed/withdrawn rats. Statistical analyses revealed a
significant interaction of treatment group by environment between intra-BLA AIP and
vehicle-treated groups (Figure 2.2h; F(1, 13) = 6.441, p = .02). Rats receiving 500 ng of
AIP (n = 8) showed no preference for morphine vs saline-paired environments (p > .05)
vs those receiving intra-BLA vehicle (n = 7), who spent significantly more time in the
morphine environment (p < .01). Thus, within the BLA-mPFC circuit, blockade of
CaMKII signaling reveals a behavioral double dissociation as a function of opiate
exposure state: CaMKII signaling is required for intra-BLA opiate reward memory
acquisition in the chronic opiate exposure/withdrawn state, but not naïve states. In
contrast, intra-mPFC CaMKII signaling is required for opiate reward memory acquisition
in the opiate-naïve, but not chronic exposure/withdrawn states.

2.3.4

Chronic Opiate Exposure and Spontaneous Withdrawal
Alters the Expression and Function of Intra-mPFC D2R
Receptor Transmission

Our present results show that intra-mPFC CaMKII signaling is required for opiate
memory formation exclusively in the opiate-naïve state (Figure 2.2e) and that intra-mPFC
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CaMKIIα levels are markedly elevated in the opiate exposed and withdrawn state (Figure
1a and b). Remarkably, these results are in the opposite direction to those observed
previously in the BLA wherein intra-BLA CaMKIIα signaling is functionally linked to
D2R transmission only in the chronic opiate exposure/withdrawn state, concomitant with
a significant downregulation in CaMKIIα levels (Lyons et al, 2013). Thus, we
hypothesized that upregulation of CaMKIIα levels in the mPFC may be linked to
opposing roles for intra-mPFC D2R transmission as a function of opiate exposure state.
Accordingly, we next examined the effects of D2R blockade directly in the mPFC,
comparing the opiate-naïve with chronic exposure/withdrawn states. Consistent with our
hypothesis, intra-mPFC D2R blockade with the selective D2R antagonist, eticlopride (1
μg/0.5 μl; n = 7) blocked acquisition of morphine CPP in the naïve, but not in the chronic
exposure/withdrawn states (Figure 2.3a and b). For opiate-naïve groups, two-way
ANOVA revealed a significant effect of conditioning environment (F(1, 14) = 4.76, p <
.05), but no significant group effect (F(1, 13) = 2.20, p = .16; Figure 2.3a). However, posthoc analyses revealed that rats treated with eticlopride (n = 7) exhibited no preference for
the morphine-paired environment (p > .05), whereas vehicle controls (n = 7)
demonstrated significant CPP (p < .05). In contrast, in chronically opiate exposed/
withdrawn rats, intra-mPFC D2R inhibition failed to block morphine CPP. Two-way
ANOVA revealed a significant main effect of conditioning environment (F(1, 12) = 38.43,
p < .01; Figure 2.3b). Post-hoc analyses demonstrated that both vehicle-treated (n = 7)
and eticlopride-treated (n = 5) groups exhibited significant preferences for morphinepaired environments (p-values < .01, < .05, respectively). Thus, blockade of D2R
transmission in the mPFC selectively blocks morphine reward CPP in the opiate-naïve
state, in direct contrast to the role of intra-BLA D2R transmission during opiate reward
memory formation (Lyons et al, 2013). Given our observed behavioral dissociation in the
role of intra-mPFC D2R transmission as a function of opiate exposure state, we next
measured levels of intra-mPFC D2R protein expression between the two exposure states.
A representative western blot of D2R expression levels is pictured in Figure 2.3c.
Interestingly, levels of D2R expression showed a significant increase in chronically
exposed/withdrawn rats (n = 8) as compared with opiate-naïve (n = 8) groups (Figure
2.3d; t(14) = − 2.659, p = .01), demonstrating that chronic opiate exposure/spontaneous
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withdrawal triggers a compensatory upregulation of D2R expression within the mPFC,
concomitant with a lack of sensitivity to D2R blockade during the acquisition of opiate
reward memories, relative to the opiate-naïve state.

Figure 2.3 Assessment of intra-mPFC D2 function and expression in animals
following chronic opiate exposure
Chronic heroin exposure alters function and expression of intra-mPFC D2R transmission.
(a) Intra-mPFC microinfusion of 1 μg eticlopride blocked the acquisition of a morphine
(5 mg/kg) CPP in the opiate-naïve state. (b) In the opiate chronic exposure/withdrawn
state, a 1 μg eticlopride infusion into the mPFC did not block the acquisition of a 5 mg/kg
morphine CPP. (c) Representative western blot of D2R expression in the mPFC between
the opiate-naïve and chronic exposure/withdrawn states. (d) D2R expression is increased
in the mPFC of opiate chronic exposure/withdrawn animals (*p < 0.05, **p < 0.01; error
bars represent SEM).
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2.3.5

Chronic Opiate Exposure Alters ERK1 Phosphorylation in
the mPFC

Previous studies have demonstrated a state-dependent switch in the roles of the intraBLA D1-ERK1/2 signaling pathway in the formation of opiate reward memories (Lintas
et al, 2011; Lyons et al, 2013). Accordingly, we next tested for changes in protein
expression and behavioral functions of the intra-mPFC D1-ERK1/2 pathway between the
opiate-naïve and chronic exposure/withdrawn states. Representative western blots of
phosphorylated and total ERK1/2 are presented in Figure 2.4a. Examining expression
levels of intra-mPFC ERK isoforms across opiate exposure states revealed a significant
increase in the expression of ERK1 phosphorylation between the opiate-naïve (n = 7) and
chronic exposure/withdrawn states (n = 7; t(12) = − 2.231, p < .05; Figure 2.4b), but no
change to total ERK1 levels (tERK1: t(12) = − 0.650, p = .361; Figure 2.4b).
Consequently, the ratio of phosphorylated to total ERK1 expression was significantly
increased in favor of pERK1 following chronic heroin exposure (t(12) = − 2.646, p < 0.05;
Figure 2.4c). Levels of phosphorylated and total ERK2 in the chronic
exposure/withdrawn state were not statistically different from the naïve state (Figure
2.4d; pERK2: t(12) = − 1.232, p = .241; tERK2: t(12) = 0.110, p = .914), and thus no
change was seen in the ratio of phosphorylated to total ERK2 (Figure 2.4e; t(12) = − 1.592,
p = .137). Given prior evidence demonstrating a functional relationship between
alterations in intra-BLA ERK1/2 expression levels with the function of D1R transmission
during opiate reward memory formation (Lyons et al, 2013), we next tested expression
levels of the D1R directly within the mPFC. Western blots comparing the expression of
DA D1Rs showed no difference in the expression of D1R between saline control and
opiate chronic exposure/withdrawn rats (Figure 2.4f and g; t(12) = − 0.317, p = .756),
demonstrating that, in contrast to the BLA, intra-mPFC alterations in ERK1 expression
are not concomitant with changes in expression levels of the D1R.
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Figure 2.4 Intra-mPFC function and expression of D1-ERK1/2 function and
expression in animals following chronic opiate exposure
Effect of chronic opiate exposure on the function and expression of ERK1/2 and
expression of D1R in the mPFC. Panel (a) illustrates a representative western blot of
phosphorylated ERK1/2 and total ERK 1/2. (b) Western blot analysis revealed a
significant increase in phosphorylated ERK1, but not total ERK1 following chronic
heroin exposure. (c) The ratio of phosphorylated to total ERK1 was significantly
increased in opiate chronic exposure/ withdrawn animals. (d) Levels of phosphorylated
ERK2 and total ERK2 were not significantly altered in opiate chronic
exposure/withdrawn groups. (e) The ratio of phosphorylated to total ERK2 was
unchanged in opiate exposure/withdrawn animals. (f) Representative western blot of D1R
expression in the mPFC. (g) Chronic heroin exposure does not alter the expression of
D1R protein. Intra-mPFC microinfusion of 1 μg PD334581 did not block the acquisition
of a morphine CPP in either the opiate-naïve state (h) or in the opiate chronic
exposure/withdrawn state (i) (*p < 0.05, **p < 0.01; error bars represent SEM).
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2.3.6

Intra-mPFC ERK1 Signaling is not Required for Opiate
Memory Formation in Either the Opiate Naïve or the Opiate
Chronic Exposure/Withdrawn States

To examine the potential behavioral significance of the observed alterations in pERK1 in
chronic exposure/ withdrawn mPFC tissue, we next tested the effect of ERK inhibition on
the acquisition of a morphine CPP. Here, we used a pharmacologically selective ERK1
inhibitor, PD334581 (1 μg/0.5 μl), to directly examine the potential functional role of
changes to pERK1 levels in opiate chronic exposure/withdrawn rats, given our findings
that ERK1, but not ERK2 phosphorylation levels are altered as a function of chronic
heroin exposure.
Two-way ANOVA revealed that selective inhibition of ERK1 in the mPFC had no effect
on the acquisition of morphine CPP in the opiate-naïve state. There was no observed
effect of treatment group (Figure 2.4h; F(1, 13) = 2.08, p = .17), but we did observe an
effect of conditioning environment (F(1, 14) = 39.45, p < .01). Post-hoc analyses revealed
that rats showed a significant morphine CPP following either intra-mPFC vehicle (n = 7;
p < .01, as above) or PD334581 (n = 7; p < .01). Furthermore, inhibition of ERK1 in the
mPFC had no effect on morphine CPP in the opiate chronic exposure/withdrawn state
(Figure 4i). Statistical analyses revealed no effect of drug treatment (F(1, 13) = 3.54, p =
.08) and a significant effect of conditioning environment (F(1, 14) = 41.24, p < .01).
Groups receiving intra-mPFC microinfusion of vehicle (n = 7) or 1 μg PD334581 (n = 7)
both demonstrated a significant preference for the morphine-paired environment (pvalues < .01).

2.3.7

Integrated ERK and CaMKII Signaling in the BLA-mPFC
Circuit is Required for Opiate Reward Memory Acquisition

Thus far, the present results show that in the opiate-naïve state, intra-mPFC CaMKII (but
not ERK) signaling is necessary for opiate reward memory formation. In contrast, in the
BLA, opiate reward memory acquisition requires ERK (but not CaMKII) signaling
specifically in the opiate-naïve state (Lyons et al, 2013). Given this BLA-mPFC
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dissociation and previous evidence suggesting that the processing of opiate reward
memory requires functional connectivity between the BLA and mPFC (Gholizadeh et al,
2013; Sun and Laviolette, 2012), we next examined if integrated activity involving intraBLA ERK and intra-mPFC CaMKII signaling is necessary for the acquisition of
morphine reward memories. We tested this hypothesis by functionally disconnecting the
effects of intra-BLA ERK signaling from intra-mPFC CaMKII signaling by
simultaneously blocking intra-BLA ERK signaling in one hemisphere (U0126; 1 μg/ 0.5
μl) and intra-mPFC CaMKII signaling (AIP; 0.5 μg/0.5 μl) in the contralateral
hemisphere (n = 5) before morphine CPP conditioning (see Materials and methods
section). In contrast, control groups received either intra-BLA combined with intra-mPFC
vehicle infusions (n = 7), intra-BLA ERK inhibition (U0126, 1 μg/0.5 μl, n = 7) paired
with intra-mPFC vehicle infusions, or intra-mPFC CaMKII inhibition (AIP; 0.5 μg/0.5
μl) paired with intra-BLA vehicle infusions (n = 6). A schematic representation of these
experimental conditions is presented in Figure 2.5a.
Two-way ANOVA revealed a significant interaction between conditioning environment
and treatment (F(3, 21) = 5.61, p < .01; Figure 2.5b). Post-hoc analyses revealed that intraBLA/intra-PFC vehicle microinfusions, unilateral blockade of intra-BLA ERK activity,
and unilateral inhibition of intra-mPFC CaMKII activity all left the acquisition of a
morphine CPP intact (p-values < .01). Unilateral intra-BLA ERK blockade paired with
contralateral mPFC CaMKII inhibition completely blocked the formation of morphine
CPP, with rats showing no preference for morphine vs saline-paired environments at
testing (p > .05). Thus, contralateral disconnection of intra-BLA ERK from intra-mPFC
CaMKII signaling during morphine CPP acquisition is sufficient to prevent morphine
CPP reward memory formation.

61

Figure 2.5 The BLA-mPFC circuit is required for opiate reward memory
acquisition
Functional dissociation of the BLA-mPFC pathway in morphine CPP acquisition. (a)
Schematic representation of experimental protocol for blocking the signaling molecules
necessary for acquisition of a morphine CPP in the opiate-naïve state. (b) Unilateral intraBLA microinfusion of 1 μg UO126 is insufficient to block the acquisition of a morphine
(0.5 mg/kg) CPP, whereas unilateral intra-BLA microinfusion of 1 μg UO126 and
contralateral intra-mPFC microinfusion of 500 ng AIP blocks the acquisition of a
morphine CPP (**p < s0.01; error bars represent SEM).
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2.4 DISCUSSION
The BLA-mPFC circuit is critical for the processing of opiate-related reward information
(Lintas et al, 2011, 2012; Lyons et al, 2013; Sun and Laviolette, 2012; Sun et al, 2011).
Importantly, bi-directional connections between the BLA and mPFC have been
demonstrated to strongly modulate opiate-related reward memory and learning at the
behavioral, neuronal, and temporal levels of analysis. For example, at the cortical level,
the activity patterns of mPFC neuronal sub-populations are correlated with the encoding,
recall, and extinction of opiate-related reward memory (Sun and Laviolette, 2012; Sun et
al, 2011). Functional connections between the BLA and mPFC are required for the
temporal transfer of associative opiate reward memories and inactivation of the BLA
modulates the neuronal activity dynamics of mPFC, and regulates the acquisition and
extinction of these memories (Gholizadeh et al, 2013; Sun and Laviolette, 2012).
Nevertheless, the molecular mechanisms involved in BLA-mPFC circuit dynamics during
the acquisition of opiate reward memories are not well understood.
Previous reports have demonstrated that opiate exposure state functions as a dynamic
functional boundary between the roles of both the D1R and D2R systems and
downstream molecular memory signaling molecules, including the ERK1/2 and
CaMKIIα pathways, specifically within the BLA (Lintas et al, 2011; Lyons et al, 2013).
Consequently, in the opiate-naïve state, acquisition of opiate reward memory requires
ERK1/2 and D1R-dependent substrates within the BLA. However, following chronic
opiate exposure and spontaneous withdrawal, intra-BLA opiate reward memory
formation switches to a D2R, CaMKIIα-dependent signaling substrate (Lyons et al,
2013). In this study, we report that the role of the mPFC in the acquisition of opiate
reward memories follows the opposite molecular memory pattern as a function of
exposure state; that is, D2R-CaMKII-dependent signaling is required only in the opiatenaïve state, but not in the chronic exposure/withdrawn state, and both D2R and CaMKIIα
expression levels are strongly increased as a function of chronic opiate exposure and
spontaneous withdrawal. In stark contrast, in the BLA, chronic opiate
exposure/spontaneous withdrawal induces a marked down-regulation of CaMKIIα and
ERK1/2 expression patterns (Lyons et al, 2013). Interestingly, although inhibition of
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ERK1/2 signaling in the BLA was shown previously to block opiate reward memory
formation specifically in the opiate-naïve state (Lyons et al, 2013), in this study,
inhibition of intra-mPFC ERK signaling was not sufficient to impair opiate reward
memory formation, regardless of exposure state. This was the case despite the
observation that chronic opiate exposure and spontaneous withdrawal induced an
upregulation specifically in the ERK1 isoform within mPFC tissue. It is important to note
that the intra-mPFC modulation of ERK1 levels shown here was substantially lower in
magnitude to changes in intra-BLA ERK1/2 levels observed previously (Lyons et al,
2013) and, similar to CaMKIIα levels, was in the opposite direction (increased vs
decreased expression levels as a function of opiate exposure state). Although beyond the
scope of this study, an alternative possibility is that other signaling pathways may be able
to compensate for ERK1 activity in the presence of ERK1 antagonism.
Forebrain CaMKIIα is necessary for contextual learning, specifically at the time of
memory acquisition (Achterberg et al, 2014), consistent with our findings that intramPFC CaMKII inhibition during reward conditioning results in the blockade of morphine
CPP acquisition. Furthermore, we have reported previously that intra-mPFC CaMKII
signaling is necessary for the consolidation of acute opiate reward memories (Gholizadeh
et al, 2013). At the molecular level, the observed increase in mPFC CaMKII expression is
consistent with similar studies of region-specific increases of CaMKII following chronic
morphine exposure (Chen et al, 2008; Narita et al, 2004). One study investigating
potential biomarkers of chronic opiate exposure also found increased levels of Ca2+ in the
serum of active heroin users (Divsalar et al, 2014). Interestingly, we observed a highly
specific alteration in the total levels of the CaMKIIα isoform within the mPFC following
chronic opiate exposure and spontaneous withdrawal, which was not observed in either
the CaMKIIβ or CaMKIV isoforms. Furthermore, no significant alterations were
observed in mPFC expression levels of calcineurin A. The present results show
alterations in the functional role of the D2-CaMKII pathway, with CaMKII and D2
inhibition preventing the formation of a morphine reward memory in the naïve, but not
the chronic exposure/ withdrawn opiate exposure states. Whether chronic opiate exposure
and spontaneous withdrawal results in alterations to D2 directly to affect downstream
CaMKII expression, or whether CaMKII levels influence the expression of D2 is
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unknown. It has, however, been suggested that alterations in D2 receptor trafficking
reduces the expression of intra-mPFC CaMKII (Papaleo et al, 2012) and not vice versa.
CaMKIIα signaling is functionally linked to D2R function. For example, previous reports
have found that CaMKIIα is bound to an intracellular domain of the D2R both in vitro
and in vivo, within the striatum (Zhang et al, 2014). Modulation of CaMKII activity
controls D4 receptor function within the mPFC during the acquisition of fear-related
memories (Lauzon et al, 2012) and CaMKIIα has been reported to control activitydependent function of striatal D3 receptors by increasing their phosphorylation, thereby
controlling D3 receptor-mediated responses to the psychostimulant effects of cocaine
(Liu et al, 2009). Although the modulatory role of CaMKIIα on prefrontal cortical D2
receptor substrates is not currently understood, the present evidence demonstrates for the
first time, convergent increases in both total levels of CaMKIIα and increased D2
receptor expression following chronic opiate exposure. Furthermore, these molecular
alterations corresponded to a loss in sensitivity of D2R receptor function in the
modulation of opiate reward memory formation, dependent upon drug exposure state,
consistent with previous reports linking CaMKIIα with D2R functional parameters, both
in vitro and in vivo, in subcortical regions.
In addition, it is possible that increased intra-mPFC D2R and/or tCaMKIIα expression in
the opiate chronic exposure/ withdrawn state renders D2-CaMKII-dependent memory
mechanisms resistant to antagonism by pharmacological manipulation. Increased
expression of tCaMKIIα may also reflect the formation of a stronger, more stable opiate
reward memory, as cortical CaMKIIα expression has been associated with the
consolidation and permanence of classical conditioning memories (Frankland et al, 2001;
Naskar et al, 2014). Increased expression of tCaMKIIα may also indicate a sensitized
response to the exposure of an opiate-related cue (ie, the morphine environment). Given
our findings of increased cortical D2R expression following chronic opiate exposure, it is
of interest that previous reports have demonstrated decreased D2R function in subcortical
brain regions involved in drug-reward processing. For example, heroin addicts display
downregulated D2R expression levels in the striatum (Martinez et al, 2012; Wang et al,
1997), suggesting a hypo-function of mesolimbic inputs to striatal regions. Although we
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are not aware of any imaging studies demonstrating increased prefrontal cortical D2R
expression levels in the opiate chronic exposure state, our findings may suggest that
subcortical vs cortical DAergic transmission patterns are differentially altered in states of
spontaneous withdrawal. Indeed, given that intra-BLA molecular and pharmacological
DA function is opposite to that observed in the mPFC as a function of opiate exposure
state, the present findings suggest important functional differences between cortical vs
subcortical regulation of DA receptor function as a function of opiate exposure state.
The observed increase in mPFC pERK1 expression is consistent with previously reported
increases in prefrontal cortical pERK following spontaneous withdrawal from chronic
heroin self-administration (Edwards et al, 2009). Although intra-BLA ERK signaling has
previously been shown to be necessary for opiate reward memory formation in the drugnaïve state (Lyons et al, 2013), the lack of behavioral effect of ERK inhibition in the
mPFC remains consistent with data from Gholizadeh et al (2013), wherein acute opiate
memory consolidation was shown to be ERK dependent in the BLA, but ERK
independent in the mPFC. Whether changes to ERK activation or expression
demonstrates a behaviorally relevant role in intra-mPFC opiate reward memory
processing at other stages of memory processing (ie, later stage consolidation or retrieval)
is still unknown. Alternatively, a significant increase in pERK1 activation following
chronic heroin administration could render antagonism of ERK1 more difficult to
achieve, and thus masking the behavioral effects of intra-mPFC ERK blockade. Finally,
given that ERK1/2 is involved with many other molecular pathways, it is possible that the
observed increase in pERK1 following chronic heroin exposure was mediated by an
upstream change that does not involve the D1R, further suggested by our findings that
increased expression in ERK1 levels did not correspond to any observable changes in the
expression levels of intra-mPFC D1R.
Consistent with previous reports demonstrating a functional interplay between the BLA
and mPFC during opiate reward memory processing (Gholizadeh et al, 2013; Sun and
Laviolette, 2012), we found that simultaneous contralateral disconnection of intra-BLA
ERK from intra-mPFC CaMKII signaling was sufficient to block opiate reward memory
formation. In contrast, unilateral inhibition of ERK signaling was not sufficient for this
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effect. Given that we observed a functional switch in the roles of both the D2R and
CaMKII signaling as a function of opiate exposure state, which occurred in the opposite
direction to that reported previously in the BLA (Lyons et al, 2013), future studies are
required to more fully characterize how intra-BLA ERK activity may regulate associative
neuronal activity in the mPFC and vice versa. Furthermore, an investigation into how
these functional switches in the role of D2R and CaMKII signaling may impact the
functioning of circuitry related to the formation of more naturalistic rewards, such as
sucrose, would be an interesting extension of these results. Nevertheless, the present
findings further implicate the functional importance of BLA-mPFC interconnectedness,
both in terms of DAergic transmission and molecular substrates linked to memory
processing during the opiate addiction process.
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Chapter 3

3

OPIATE EXPOSURE STATE CONTROLS DOPAMINE
D3 RECEPTOR AND CDK5/CALCINEURIN
SIGNALING IN THE BASOLATERAL AMYGDALA
DURING REWARD AND WITHDRAWAL AVERSION
MEMORY

Adapted from Prog Neuropsychopharmacol Biol Psychiatry. 2017 Oct 3;79(B):59-66.
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3.1 INTRODUCTION
Chronic exposure to opiates can induce plastic alterations in dopamine (DA) receptor
function in brain regions involved in associative memory formation (Lintas et al., 2011,
2012). One such area, the basolateral nucleus of the amygdala (BLA), contains high
levels of the dopamine (DA) D3 receptor (D3R; Gurevich and Joyce, 1999; Vorel et al.,
2002; Beaulieu and Gainetdinov, 2011; Avalos-Fuentes et al., 2013), a member of the D2
receptor family that is critically involved in addiction-related memory processing (Yan et
al., 2013). Indeed, D3R transmission in the amygdala influences the acquisition and
expression of appetitive Pavlovian behaviors and opiate-related associative memory cues
(Hitchcott and Phillips, 1998; Galaj et al., 2015). Chronic exposure to drugs of abuse has
been shown to induce plastic adaptations in the D3R system as demonstrated in postmortem tissue from cocaine (Staley and Mash, 1996; Segal et al., 1997) and opiatedependent individuals (Cosgrove, 2010). Furthermore, D3R-related genetic
polymorphisms have been observed in individuals expressing early-onset heroin
dependence (Kuo et al., 2014) and in those with a history of heroin addiction (Levran et
al., 2014). Nevertheless, the precise functional role of intra-BLA D3R transmission in the
processing of opiate-related learning and memory is not well understood.
Associative memory processing in the BLA involving select DA receptor subtypes and
their downstream signaling cascades have been identified as critical players in opiaterelated learning and memory (Lintas et al., 2011). For example, previous evidence has
identified an intra-BLA, dopamine (DA) receptor-mediated, switching mechanism
controlling the acquisition of opiate reward memories as a function of previous opiate
exposure history and withdrawal state (Lyons et al., 2013). Specifically, intra-BLA D1
receptor (D1R) transmission and downstream modulation of the extracellular signalrelated kinase (ERK) pathway, is critical for opiate reward memory formation during the
early, non-dependent phase of opiate-related memory processing. However, following
chronic opiate exposure and dependence, intra-BLA opiate-memory formation
functionally switches to a D2 receptor (D2R) substrate associated with the
calcium/calmodulin-dependent kinase II (CaMKII) memory signaling pathway (Lintas et
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al., 2011). Thus, functional and molecular alterations in the D2R family represent
important amygdala adaptations during the opiate addiction process.
Given its relatively high concentration in the BLA and its established role in drug-related
learning and memory, the D3R is a potential candidate for processing opiate-related
associative memory in the BLA. The D3R is linked both to the cyclin-dependent kinase 5
(Cdk5) pathway and calcineurin downstream molecular pathways (Chergui et al., 2004;
Chen et al., 2009; Liu et al., 2009; Avalos-Fuentes et al., 2013), both of which play
important roles in synaptic plasticity and the formation of conditioned reward memory
(Mansuy et al., 1998; Biala et al., 2005; Baumgärtel and Mansuy, 2012; Lyons et al.,
2013). However, how chronic opiate exposure may alter the functional activity state of
the D3R within the BLA and its downstream molecular pathways is not currently
understood, especially in the context of opiate-related memory formation.
The aim of the present study was to examine how intra-BLA D3R transmission may
regulate the formation of both opiate-related reward and withdrawal aversion-related
associative memory formation. In addition, we examined how chronic opiate exposure
may alter the functional role and expression levels of intra-BLA D3R and its downstream
eﬀects on the Cdk5/calcineurin signaling pathways. Using both reward and withdrawal
aversion place conditioning procedures combined with intra-BLA molecular protein
analyses in rats, we report that chronic opiate exposure and withdrawal causes profound
changes in intra-BLA D3R expression and function during the formation of both opiate
reward and withdrawal aversion associative memories. Furthermore, these opiate-related
alterations are dependent upon concomitant alterations in the function and expression of
the D3R-linked signaling pathways, calcineurin and Cdk5.

3.2 MATERIALS AND METHODS
3.2.1

Surgical procedures

All procedures were performed in accordance with the Canadian Council on Animal Care
and approved by the Western University Council on Animal Care. Male Sprague-Dawley
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rats (350–400 g; Charles River) were anesthetized with ketamine/xylazine (80 mg and 6
mg/kg, respectively), given 1 mg/kg of meloxicam (non-steroidal anti-inflammatory
analgesic) and placed into a stereotaxic device. Stainless steel guide cannulae (22 gauge;
PlasticsOne) were bilaterally implanted into the BLA based on anatomical boundaries
defined by Paxinos and Watson (2005) as follows: (no angle), from bregma, AP −2.6,
ML + 5.0, DV −7.2.

3.2.2

Drug treatments

The selective D3R antagonist, PG01037 dihydrochloride (PG01037; 133-fold selective
over D2R; Tocris Bioscience), Calcineurin auto-inhibitory peptide (calAIP; Tocris
Bioscience), morphine (morphine hydrochloride, MacFarlane Smith) and heroin
(diacetyl-morphine, MacFarlane Smith) were dissolved in physiological vehicle (0.9%
NaCl; saline), pH adjusted to 7.4. The competitive Cdk5 antagonist Roscovitine (SigmaAldrich) was dissolved in a 50% DMSO and physiological vehicle solution. All intraBLA drug or vehicle microinjections (0.5 μL per infusion) were delivered via tubing
connected to a 1 μL Hamilton microsyringe over 1 min. Injectors were left in situ for an
additional 1 min to ensure diﬀusion from the injector tip. For all groups, micro-infusions
were performed immediately prior to injections of morphine or vehicle (i.p.) and
subsequent placement in the conditioning environment. The dose of morphine used for
CPP (5 mg/ kg, i.p.) is a supra-reward threshold conditioning dose, and produces robust
behavioural CPP (Sun et al., 2011; Lyons et al., 2013).

3.2.3

Comparison of opiate exposure states

Experimental groups consisted of non-dependent (i.e. rats that were previously naïve to
opiates at the beginning of behavioural or molecular experiments) or chronically exposed
and in withdrawal (i.e. rats that were chronically opiate exposed and in a state of
withdrawal at the time of behavioural or molecular experiments), as previously described
(Lintas et al., 2011; De Jaeger et al., 2013; Lyons et al., 2013; Rosen et al., 2015). For
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chronic opiate exposure/withdrawal groups, rats were pretreated with once-daily
injections of 0.5 mg/kg heroin (s.c.) in their home cage starting 7 days prior to
behavioural conditioning. The first conditioning session began 21 h following the last
heroin injection. During the conditioning procedure, maintenance doses of heroin were
administered 2.5 to 3 h after the end of each conditioning session, for a total of 15
injections over the course of an experiment. Non-dependent rats received vehicle
injections over the same time course, in place of heroin. This regimen produces aversive
motivational eﬀects (CPA) similar to those produced by a 3-weeks of morphine
administration (Bechara et al., 1995; Laviolette and van der Kooy, 2004), thus indicating
a state of potent opiate dependence. An outline of exposure states is illustrated in Fig.
3.1A.

Figure 3.1 Outline of treatment conditions and experimental timeline
Experimental design and timeline. (A) Outline of two opiate exposure conditions. (B)
Schematic outlining experimental timeline for conditioned place preference (CPP) and
conditioned place aversion (CPA) paradigms.
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3.2.4

Place preference conditioning

An unbiased, fully counterbalanced place conditioning paradigm was used, as described
previously (Lintas et al., 2011; Lyons et al., 2013). All rats (n = 117) were given one
week to recover from surgery before habituation for 20 min in a motivationally neutral
grey box. Rats were then randomly assigned to an experimental group, and the
conditioning procedure began the following day. One conditioning environment was
white with a woodchip and wire mesh floor, and the alternate environment was black
with a Plexiglas floor, wiped down with 0.25 mL of 2% acetic acid. Thus, the two
conditioning environments diﬀered in terms of texture, odor and colour. As described
previously, these two conditioning environments elicit no baseline preference in rats
(Laviolette and van der Kooy, 2003). Rats spent an equal number of 30-min conditioning
sessions in morphine-paired and vehicle-paired environments (i.e. four morphineenvironment pairings and four vehicle-environment pairings over the 8-day procedure).
Testing was carried out in a drug-free state 7 days following the final conditioning
session. The test environment consisted of both conditioning environments separated by a
neutral grey zone. Rats were placed onto the neutral zone at the start of the test and
allowed to freely explore the arena for 10 min while time spent in each environment was
independently recorded.

3.2.5

Opiate withdrawal conditioned place aversion procedure

To study the eﬀects of the D3R and its downstream targets on the acquisition of a CPA to
environments paired with opiate withdrawal, an adapted CPA paradigm was used
(Laviolette et al., 2002). In the single-side opiate withdrawal procedure, rats are exposed
to only one of the two conditioning environments described above. Opiate dependent/
withdrawn rats are placed into the environment immediately following microinfusion 21
h following their previous heroin injection (i.e. during withdrawal), and receive a
maintenance dose of heroin 2.5 to 3 h following removal from the box, as per the CPP
paradigm. Withdrawal conditioning environments were randomly assigned and counter-
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balanced across groups. Rats (n = 40) received four exposures to the conditioning
environment. As per the CPP procedure, rats were given a 7-day recovery period before
testing in a drug-free state. Upon testing, rats will typically spend significantly less time
in the environment in which they experienced aversive eﬀects of withdrawal (Bechara et
al., 1995), i.e. they form a CPA to the withdrawal environment. Previous studies have
found this paradigm to be sensitive to both spontaneous and naloxone-precipitated
withdrawal, and to not confounded by any novelty eﬀects of the non-withdrawal
environment upon testing (Bechara et al., 1995; Laviolette et al., 2002). An outline of
both place preference and withdrawal aversion paradigms is presented in Fig. 3.1B.

3.2.6

Western blot procedure

Rats received 15 daily injections of either physiological vehicle (non-dependent group) or
heroin (chronic exposure group; 0.5 mg/kg, s.c.), equivalent to the injections received by
the experimental groups (opiate naïve vs. heroin exposed/withdrawn, n = 8 per group)
rats used for behavioural pharmacology experiments. The tissue extraction and western
blot procedure was performed as outlined in Lyons et al., 2013. Primary antibody
dilutions were as follows: D1R (1:100; sc-14,001; Santa Cruz Biotechnology), D3R
(1:100; sc-9114; Santa Cruz Bio-technology), phosphorylated Cdk5 [Tyr 15] (pCdk5;
1:100; Santa Cruz Biotechnology), Cdk5 (1:200; Santa Cruz Biotechnology), Calcineurin
A (CnA; 1:100,000; Sigma-Aldrich) and α-tubulin (1:120,000; Sigma-Aldrich). All
secondary antibodies (Thermo Scientific) were used at a 1:20,000 dilution. Blots were
incubated in a TBS-T solution with either 2.5% Bovine Serum Albumin Fraction V
(Calbiochem) or 5% non-fat dried milk (Carnation) as recommended by the
manufacturer.

3.2.7

Histology

Upon the conclusion of behavioural experiments, rats were anesthetized with Euthanyl
(sodium pentobarbital, 240 mg/kg, i.p.) and transcardially perfused with 0.9%
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physiological vehicle and 10% formalin. Brains were extracted and refrigerated in a 25%
sucrose in formalin solution at 4 °C for a minimum of 48 h. Brains were then sliced at 60
μm and stained with Cresyl Violet to allow for verification of cannula placements.
Subjects with placements outside the anatomical boundaries (n = 20 out of 137 total) of
the BLA as defined by Paxinos and Watson (2005) were excluded from analysis.

3.2.8

Data analysis

Conditioned place preference and conditioned place aversion data were analyzed with
two-way analysis of variance (ANOVA), and post hoc analyses were performed with
Fisher's least significant diﬀerence (LSD) test where appropriate. Densitometry values for
western blots were obtained with Kodak digital analysis software and analyzed with twotailed t-tests.

3.3 RESULTS
3.3.1

Chronic opiate exposure and withdrawal selectively
downregulates intra-BLA D3R expression

While previous reports have demonstrated that chronic opiate exposure and withdrawal
leads to a selective decrease in intra-BLA D2-like receptor expression (Rosen et al.,
2015; Lyons et al., 2013), the precise D2R subtype involved in these eﬀects is not known.
Thus, to determine the potential involvement of intra-BLA D3R subtype plasticity across
opiate exposure states, we first measured and compared expression levels of intra-BLA
D3R vs. D1R levels in either non-dependent or chronically exposed and withdrawn rats
(see Section 3.2.3). Example western blots illustrate the expression levels of D3R and
D1R between a opiate exposure states in Fig. 3.2A and B, respectively. Interestingly, rats
that have been exposed to chronic opiates express a selective downregulation of the D3R
(Fig. 3.2C, n = 7, t(12) = 2.276, p = .042), but not the D1R (Fig. 3.2D, n = 8, t(14) = 0.984,
p = .342).
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Figure 3.2 Expression of intra-BLA D1R and D3R following chronic heroin
exposure
Chronic heroin differentially alters the expression of dopamine receptor subtypes
in the BLA. (A) Representative western blot for D3R expression. (B) Densitometry
analysis revealed a significant downregulation of the D3R in response to chronic heroin
exposure (saline n = 7, heroin n = 7). (C) Representative western blot for D1R
expression. (D) Densitometry analyses revealed that chronic heroin does not significantly
alter the expression of the D1R. (saline n = 8, heroin n = 8). Asterisks represent p < .05.
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3.3.2

Effects of intra-BLA D3R blockade on morphine reward CPP
in the opiate-naïve state

We first examined the potential role of intra-BLA D3R blockade on the formation of a
morphine reward CPP (5 mg/kg; i.p.) in rats with no previous history of opiate exposure
(see Section 3.2.4). Histological analyses confirmed the placements of microinjector tips
within the anatomical boundaries of the BLA as defined by Paxinos and Watson (2005).
A microphotograph and schematic of intra-BLA placement (Fig. 3.3A, B) presents
placements of representative experimental groups. We first tested three intra-BLA
challenge doses of the selective D3R antagonist, PG01037 (10 ng, 100 ng and 1000
ng/0.5 μL) (Fig. 3.3C). Two-way ANOVA revealed no treatment eﬀect of the D3R
antagonist relative to rats receiving intra-BLA vehicle (F(3,27) = 2.830, p = .156), but a
main eﬀect of conditioning environment (F(1,28) = 40.93 p < .001). Post-hoc analyses
revealed that rats receiving intra-BLA vehicle (n = 6), 10 ng PG01037 (n = 8) 100 ng
PG01037 (n = 7) or 1000 ng PG01037 (n = 7), spent significantly greater amounts of time
in morphine-paired environments (p’s all < .05), thus indicating that intra-BLA D3R
antagonism had no eﬀect on the acquisition of a morphine CPP in non-opiate-exposed,
non-dependent rats.
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Figure 3.3 Assessment of intra-BLA D3R blockade on the acquisition of morphine
CPP across opiate exposure states
Antagonism of the D3R affects the acquisition of a morphine CPP in a state-dependent
manner. (A) Schematic of bilateral intra-BLA cannula placements. Open squares: intraBLA vehicle in the opiate naïve state; open circles: 100 ng intra-BLA PG01037 in the
opiate naïve state; closed circles: 1000 ng PG01037 in the chronic exposure/withdrawal
state. (B) Representative microphotograph of intra-BLA guide cannula and
microinjection tip placement. (C) Microinfusion of PG01037 in the opiate naïve state
does not inhibit the acquisition of a morphine CPP. Group n’s: saline n = 7, 10 ng
PG01037 n = 8, 100 ng PG01037 n = 7, 1000 ng PG01037 n =7. (D) Microinfusion of
PG01037 dose-dependently blocks the acquisition of a morphine CPP in the chronic
exposure/withdrawal state. Group n’s: saline n = 8, 10 ng PG01037 n = 9, 100 ng
PG01037 n = 8, 1000 ng PG01037 n = 6. (E) Microinfusion of PG01037 immediately
before testing does not result in a recovered morphine CPP. Group n’s: 100 ng PG01037
n = 8, 1000 ng PG01037 n = 6. Time (s) represents time spent in morphine- or salinepaired environment on testing day. Asterisks represent p < .05.
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3.3.3

Intra-BLA D3R antagonism blocks opiate reward memory
formation in chronically exposed and withdrawn rats

Next, we examined the eﬀect of intra-BLA D3R antagonism in rats chronically exposed
to opiates and in withdrawal. We tested three doses of intra-BLA PG01037 during
conditioning to create a full dose-response curve (Fig. 3.3D). Two-way ANOVA revealed
a significant eﬀect of conditioning environment (F(1,31) = 19.513, p < .001). Post-hoc
analyses revealed that groups receiving 100 ng (n = 8) or 1000 ng of intra-BLA PG01037
(n = 6) failed to express a morphine CPP (p’s > .05), whereas groups treated with a lower
dose of intra-BLA PG01037 (10 ng; n = 9) or vehicle (n = 8) formed a significant
preference for the morphine-paired environment (p’s < 0.05). Thus, in contrast to results
in opiate-naïve rats, intra-BLA D3 blockade prevented the acquisition of morphine
reward CPP following chronic opiate exposure and withdrawal.
Although we observed a block of CPP following conditioning with the D3R antagonist
PG01037, previous studies have reported that a failure to acquire a CPP when a DA
antagonist was applied during conditioning could be reversed by administering the
antagonist upon testing (Ting-A-Kee and Mercuriano, 2013). To rule out the possibility
of state-dependent recall of morphine CPP, we tested two groups of rats immediately
after infusion of PG01037. We used the two eﬀective doses from the initial dose response
experiment in chronically treated rats (100 ng and 1000 ng) as illustrated in Fig. 3.3E.
Two-way ANOVA revealed no eﬀect of treatment or conditioning environment (F(1,13) =
.170, p = 0.687, F(1, 14) = 2.236, p = .161, respectively). Rats in both the 100 ng group (n
= 8) and 1000 ng group (n = 8) failed to demonstrate morphine CPP, thus indicating that
the block of CPP by the D3R antagonist PG01037 in opiate exposed and withdrawn rats
is not simply due to a block of state-dependent learning.
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3.3.4

The downstream molecular targets of D3R, Cdk5 and
calcineurin, are altered following chronic opiate exposure
and withdrawal

Given our findings that chronic opiate exposure/withdrawal downregulates BLA D3R
expression and increases sensitivity to D3R blockade during morphine CPP conditioning
(Figs. 3.2, 3.3), we next explored whether these functional alterations in BLA D3R
function may be mechanistically linked to downstream changes in the Cdk5/calcineurin
signaling pathways. First, we compared the activation and expression of Cdk5 in the
BLA as a function of opiate exposure state. Fig. 3.4A shows representative western blots
of both phosphorylated and total expression levels of Cdk5 (pCdk5 and tCdk5,
respectively) across opiate exposure states. Rats chronically exposed to opiates and in
withdrawal at the time of tissue processing (n = 7) expressed a significant increase in
pCdk5 compared to vehicle-treated rats (n = 7), indicating an increase in Cdk5 activation
(Fig. 3.4B, t(12) = −2.303, p < .05). There was no observed diﬀerence in tCdk5, however,
indicating no change to cellular tCdk5 stores (vehicle n = 7, heroin n = 7; t(12) = −0.960, p
= .356). Finally, as a result of the change in phosphorylated, but not total, levels of Cdk5,
we examined the ratio of phosphorylated (active) to the total cellular pool of Cdk5 and
found a trending, though nonsignificant, change in ratio between vehicle- and herointreated tissue (t(12) = −2.021, p = .066).
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Figure 3.4 Intra-BLA Cdk5 and calcineurin expression following chronic opiate
exposure
Chronic heroin affects the expression of signaling molecules downstream of the D3R. (A)
Representative western blot for pCdk5 and tCdk5. (B) Densitometry analysis revealed a
significant upregulation of pCdk5 (saline n = 7, heroin n = 7), but not tCdk5 (saline n = 7,
heroin n = 7) following chronic heroin exposure. (C) Representative western blot for
calcineurin expression. (D) Densitometry analysis revealed a significant increase of
calcineurin following chronic heroin exposure (saline n = 7, heroin n = 7). Asterisks
represent p < .05.

In addition to Cdk5, the D3R also aﬀects downstream calcineurin signaling. We therefore
compared the expression of intra-BLA calcineurin between vehicle- and heroin-treated
rats, as shown in the representative western blot in Fig. 3.4C. An independent-samples ttest revealed a significant increase in the expression of calcineurin in rats that had been
treated with heroin and were in a state of spontaneous withdrawal at the time of tissue
processing (Fig. 3.4D, vehicle n = 7, heroin n = 7; t(12) = −2.215, p < .05).
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3.3.5

The D3R-dependent BLA memory switch is reversed by
inhibition of intra-BLA Cdk5 and calcineurin signaling

In order to test whether the observed upregulations in intra-BLA pCdk5 and calcineurin
expression following chronic opiate exposure and withdrawal are mechanistically linked
to observed changes in BLA D3R sensitivity, we next challenged the eﬀects of intra-BLA
D3R blockade with co-administration of selective Cdk5 and calcineurin inhibitors. We
hypothesized that if opiate-induced alterations to Cdk5 and calcineurin were underlying
the ability of a D3R antagonist to block CPP acquisition in the dependent/withdrawn
opiate exposure state, then the co-infusion of the D3R antagonist PG01037 with either
Cdk5 or calcineurin inhibitors would reverse the eﬀects of intra-BLA D3R blockade in
the chronically exposed and withdrawn state. Here, we used two doses (100 ng and 200
ng/0.5 μL) of the Cdk5 antagonist, roscovitine, and two doses of calAIP (50 ng and 500
ng/0.5 μL).
Two-way ANOVA revealed a significant eﬀect of conditioning environment (F(1,40) =
25.606, p < .001) on times spent in vehicle vs. morphine paired environments (Fig. 3.5).
Post-hoc analyses confirmed that the 1000 ng dose of intra-BLA PG01037 blocked the
formation of a morphine CPP, as rats spent equal amounts of time in vehicle vs.
morphine-paired environments (p > .05), whereas rats receiving intra-BLA vehicle spent
significantly more time in morphine-paired environments (p < .05). Interestingly, coinfusion of the Cdk5 antagonist with intra-BLA PG01037 dose-dependently reversed the
block of morphine CPP. Thus, whereas rats receiving 1000 ng PG01037 co-infused with
a lower dose of ros (100 ng; n = 7) still demonstrated a block of morphine CPP (p > .05),
co-infusion of PG01037 with a higher dose of roscovitine (200 ng; n = 6), reversed the
eﬀects of D3R blockade, with rats showing a significant morphine CPP (p < .05; Fig.
3.5). Similarly, co-infusion of calAIP with PG01037 dose-dependently reversed the
eﬀects of intra-BLA D3R blockade on morphine CPP. Thus, whereas rats receiving a
lower dose of calAIP (50 ng) with PG01037 (n = 6) still demonstrated a block of
morphine CPP (p > .05), rats receiving a higher dose of calAIP (500 ng) with PG01037
(n = 7) demonstrated a significant morphine CPP (p < .01; Fig. 3.5).
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Figure 3.5 Reversal of intra-BLA D3-mediated block of CPP acquisition by
administration of Cdk5 and calcineurin inhibitors
Pharmacological blockade of heroin-induced increases to Cdk5 and calcineurin restores
the D3R-dependent block of CPP acquisition in chronically exposed/withdrawn animals.
Co-infusion of Cdk5 inhibitor roscovitine (ros) dose-dependently recovers the block of
CPP acquisition by 1000 ng PG01037 (PG) in chronically exposed/withdrawn animals.
Co-infusion of calcineurin AIP (calAIP) also dose-dependently recovers the block of CPP
acquisition by 1000 ng PG01037 in chronically exposed/withdrawn animals. Data in the
D3R blockade alone section is presented again from Fig. 3.3D for ease of comparison.
Group n’s: saline n = 8, 100 ng PG01037 n = 6, 100 ng ros + PG01037 n = 7, 200 ng ros
+ PG01037 n = 6, 50 ng calAIP + PG01037 n = 6, 500 ng calAIP + PG01037 n = 7. Time
(s) represents time spent in morphine- or saline- paired environment on testing day.
Asterisks represent p < .05.

3.3.6

Opiate withdrawal aversion memory formation depends upon
intra-BLA D3R and downstream calcineurin and Cdk5
signaling

In addition to the formation of associative reward memories, the BLA is critical for the
formation of associative opiate aversion memories related to withdrawal (Frenois, 2005).
Accordingly, we next examined if intra-BLA D3R transmission may be involved in the
acquisition of aversive opiate withdrawal memories. We ran six groups of rats in a
conditioned place (withdrawal) aversion procedure (see Section 3.2.5). The results of
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opiate withdrawal CPA memory experiments are presented in Fig. 3.6. (A) Two-way
ANOVA revealed a significant treatment by environment interaction on times spent in
opiate-withdrawal paired environments during testing (F(5, 34) = 3.352, p = .014). Post-hoc
analysis revealed that rats receiving intra-BLA vehicle (n = 7) spent significantly less
time (p < .05) in withdrawal paired environments. In contrast, rats (n = 7) receiving the
previously established eﬀective dose of intra-BLA PG01037 (1000 ng), showed no CPA
(p > .05), demonstrating that intra-BLA D3R transmission is required for the acquisition
of aversive opiate withdrawal memories.
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Figure 3.6 Intra-BLA D3-Cdk5/calcineurin signaling is required for CPA
acquisition
Aversive withdrawal memories are sensitive to pharmacological manipulations of D3R
and its downstream signaling targets. (A) Microinfusion of 1000 ng PG01037 (PG)
blocks the acquisition of a CPA. Co-infusion of either roscovitine (ros) or calcineurin
AIP (calAIP) with 1000 ng PG01037 recovers the PG-induced blockade of CPA
acquisition. Group n’s: saline n = 7, 1000 ng PG01037 n = 7, 200 ng ros + PG01037 n =
5, 500 ng calAIP +PG01037 n = 7, 200 ng ros n = 8, 500 ng calAIP n = 6. (B) The block
of CPA by PG01037 is not restored by infusing 1000 ng PG01037 immediately prior to
testing. Groups receiving intra-BLA saline during conditioning, as well as those receiving
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1000 ng intra-BLA PG01037 during conditioning but not testing are presented again from
panel (A) for ease of comparison. Group n’s: saline n = 7, 1000 ng PG01037 n = 7, 1000
ng PG01037 retest n = 7. Time (s) represents time spent in withdrawal or novel
environment on testing day. Asterisks represent p < .05.
Given our previous findings demonstrating that reversing chronic-opiate induced upregulation of Cdk5 and calcineurin in the BLA reversed the eﬀects of D3R blockade on
opiate reward memory formation, we next tested if similar intra-BLA manipulations of
Cdk5 or calcineurin may reverse D3R eﬀects on opiate withdrawal memory formation.
Using the highest eﬀective doses from our previous dose-response curves, we found that
groups receiving 1000μg PG01037 co-infused with either 200 ng roscovitine (n = 5) or
500 ng calAIP (n = 7) demonstrated significant CPAs for the withdrawal environment
(p’s < .01). Thus, similar to the eﬀects of D3R blockade observed on opiate reward
memory formation, pharmacological reversal of calcineurin or Cdk5 upregulation in the
BLA fully reversed the functional eﬀects of D3R blockade on opiate withdrawal memory
formation.
Finally, we investigated whether intra-BLA administration of Cdk5 or calcineurin
inhibitors alone would be suﬃcient to block the aversive eﬀects of opiate withdrawal and
inhibit the formation of a CPA to the withdrawal environment. Indeed, administration of
intra-BLA 200 ng roscovitine (n = 8) or 500 ng calAIP (n = 6) alone resulted in the block
of an acquired CPA, as demonstrated by a lack of significant diﬀerence between the time
spent in the novel and withdrawal environments (p’s > .05). Again, to rule out the
possibility of state-dependent effects of intra-BLA D3 antagonism on withdrawalaversion memory formation during the initial CPP test, rats were re-tested in the CPP
procedure, but in the presence of intra-BLA PG01037. As with CPP experiments, this
eﬀect was not altered by the administration of intra-BLA PG01037 during the CPP
testing phase (see Fig 3.6 (B)). Animals tested in the CPA paradigm in the presence of
intra-BLA PG01037 did not spend significantly diﬀerent amounts of time in the novel or
withdrawal environments (p > .05). Thus, this suggests that intra-BLA D3 blockade of
the acquisition of CPA memories is not state-dependent.

91

3.4 DISCUSSION
Given the fundamental importance of neural learning and memory mechanisms during
the opiate addiction process, a critical question concerns how diﬀerent states of opiate
exposure and withdrawal may alter molecular memory substrates linked to the positive
and aversive motivational properties of opiates. We have previously demonstrated that
chronic opiate exposure profoundly alters intra-BLA DAergic receptor expression and
molecular memory substrates, including ERK and CaMKII (Lintas et al., 2011; Lyons et
al., 2013; Rosen et al., 2015). However, while neuroadaptations in limbic D3R expression
have been observed following chronic drug use (Le Foll et al., 2005; Cosgrove, 2010),
the functional and mechanistic role of these adaptations have yet to be investigated in the
context of BLA-dependent, opiate-related associative memory formation.
Here, we report that chronic opiate exposure results in a selective and profound downregulation of intra-BLA D3R expression. These receptor level adaptations were
associated with a functional switch in the role of intra-BLA D3R transmission during the
acquisition of both opiate associative opiate reward memories as well as memories linked
to the aversive eﬀects of opiate withdrawal. Thus, while intra-BLA D3R blockade failed
to block the formation of opiate reward memories in non-dependent rats, following
chronic opiate exposure and withdrawal, we observed a functional switch to a BLA D3Rdependent opiate memory mechanism, and increased sensitivity to intra-BLA D3R
blockade during opiate reward and withdrawal aversion memory formation. Interestingly,
these D3R receptor expression alterations were concomitant with profound upregulation
of both calcineurin and Cdk5, two signaling pathways that are linked to the functional
properties of D3R transmission (Chergui et al., 2004; Chen et al., 2009; Liu et al., 2009),
required for associative memory formation (Mansuy et al., 1998; Biala et al., 2005;
Baumgärtel and Mansuy, 2012; Lyons et al., 2013), and which are altered by chronic
drug exposure (Chiocco et al., 2011; Ramos-Miguel and García-Sevilla, 2012). These
molecular adaptations in Cdk5/calcineurin were functionally linked to D3R-dependent
memory formation, as pharmacologically inhibiting either calcineurin or Cdk5 was
suﬃcient to reverse the eﬀects of intra-BLA D3R blockade on both opiate reward and
withdrawal aversion memory formation, in the chronically exposed and withdrawn states.
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Interestingly, antagonism of either Cdk5 or calcineurin alone was suﬃcient to block the
acquisition of a CPA to the withdrawal environment. Thus, intra-BLA roscovitine or
calAIP alone was able to bypass D3 receptor-dependent modulation of associative
withdrawal memory formation, and directly reverse intracellular upregulation of Cdk5 or
calcineurin. This may suggest the potential clinical utility for these compounds to act as
targeted therapeutics for treating opiate-related withdrawal aversion memories.
Given that the D3R is a member of the D2-type receptor family, the observed switch
between the opiate naïve vs. chronically exposed and withdrawn states is consistent with
previous findings showing that opiate reward memory formation is dependent on intraBLA D2R transmission only after chronic exposure and withdrawal from heroin (Lintas
et al., 2011). Furthermore, several previous reports have demonstrated a role for intraBLA D3R activity in distinct phases of drug-related memory processing, including the
incubation and/or recall phases of drug seeking behaviors, including cocaine and nicotine
(Vorel et al., 2002; Beninger and Banasikowski, 2008; Di Ciano, 2008; Khaled et al.,
2014; Xi et al., 2014). Our observed opiate-induced alterations to D3R expression are
also consistent with preclinical reports of opiate-induced alterations in BLA D2R
expression (Rosen et al., 2015) and aberrant neural D3R expression in substance abusing
clinical populations (Le Foll et al., 2005; Cosgrove, 2010; Hou et al., 2012). While little
is known regarding how chronic opiate-dependence selectively alters D3R expression in
the human brain, previous studies have reported decreases of > 40% in the amygdala of
chronic alcoholics (Tupala et al., 2001). Furthermore, homozygosity at the D3R gene has
been linked to measures of increased sensation seeking in human heroin addicts (Duaux
et al., 1998).
Interestingly, we found that the functional eﬀects of intra-BLA D3R and associated
calcineurin and Cdk5 signaling were similar during the formation of both rewarding and
withdrawal-related aversive opiate-related memory formation, consistent with the
involvement of the BLA in processing both reward and aversion-related associative
memories (Lintas et al., 2011; Tan et al., 2011). What functional mechanism(s) may
account for the presently observed relationship between BLA D3R transmission and
calcineurin/Cdk5 signaling? One potential explanation may be related to the role of the
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D3R as a presynaptic autoreceptor with a high aﬃnity for DA (Missale et al., 1998;
Boileau et al., 2015). For example, the D3R is particularly sensitive to increases in DA
activity relative to the D1R and D2R. However, D3R activation results in inhibition of
further DA release (Tang et al., 1994; Sokoloﬀ et al., 2006; Chen et al., 2009). This
process involves D3R suppression of presynaptic GABAergic inputs (Diaz et al., 2011;
Avalos-Fuentes et al., 2013), and activation of both calcineurin and downstream Cdk5
signaling (Hernandez-Lopez et al., 2000; Chen et al., 2009). Consequently, one
possibility is that at low tonic DA activity states, the D3R remains active, suppressing
DA release (Avalos-Fuentes et al., 2013). However, in response to high levels of DA
release (e.g. following mesolimbic DA activation in states of opiate withdrawal and
increased BLA DA release (Wise, 2004; Luscher, 2013), the D3R may detect resulting
elevations in intracellular Ca2+ and become inactivated, thus causing augmented
disinhibition of BLA DA release and enhanced sensitivity to BLA DA blockade during
opiate reward learning (Liu et al., 2009).
Given that intra-BLA DA release is necessary for the formation of aﬀective associative
memories (Rosenkranz and Grace, 1999; Grace and Rosenkranz, 2002), it is conceivable
that DA release via activity-dependent deactivation of the D3R is involved in the
formation of context-dependent drug memories. Indeed, previous reports have
demonstrated that D3R modulation can influence the formation of place preference
memories for drugs of abuse (Le Foll et al., 2002; Sokoloﬀ et al., 2006). Furthermore,
functional interactions between the D3R and CaMKIIα signaling are responsible for
activity-dependent reduction in D3R eﬃcacy following high, but not low, frequency rates
of action potential firing (Liu et al., 2009; Avalos-Fuentes et al., 2013), consistent with
earlier reports that the D3R controls synaptic transmitter release only above a set spike
frequency or burst duration threshold (Kuzhikandathil and Oxford, 1999). Liu et al.
(2009) have further demonstrated that cocaine strengthens the CaMKIIα-D3R
association, and that disruption of that link subsequently restores the ability of the D3R to
attenuate responses to subsequent cocaine administration. Pairing our current finding that
the D3R is selectively downregulated following chronic opiate exposure with previous
reports of opiate-induced reductions in intra-BLA CaMKIIα expression (Lyons et al.,
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2013), one possibility is that the CaMKIIα-D3R complex is highly sensitive to
antagonism of either D3R or CaMKIIα during states of chronic opiate exposure and
withdrawal. This hypothesis is supported both by the D3R-antagonist-dependent block of
CPP and CPA formation reported here, and previous reports that CaMKIIα blockade
inhibits CPP acquisition selectively in states of chronic opiate exposure and withdrawal
(Lyons et al., 2013).
D3R activation is linked to an increase in both calcineurin and Cdk5 activation (Chen et
al., 2009). In the present study, we report that both calcineurin and Cdk5 activity are
upregulated following chronic opiate exposure, while D3R expression is selectively
downregulated. It is possible that while calcineurin and Cdk5 activity may remain
augmented following chronic opiate exposure, the D3R is downregulated as a
compensatory mechanism in response to over-stimulation by repeated opiate
administration. Over-expression of Cdk5 has been reported to increase D3R-mediated
suppression of DA release, likely via activation of calcineurin (Chen et al., 2009).
Furthermore, Cdk5 inhibitors have previously been shown to increase DA release
(Chergui et al., 2004). It is therefore possible that by blocking the chronic opiate-induced
increases to calcineurin and Cdk5 activity, any remaining D3R-mediated suppression of
DA release is removed, allowing for postsynaptic DA transmission, and the formation of
associative memory formation. Given that Cdk5 is reported to be a downstream target of
calcineurin in a D3R signaling cascade (Chen et al., 2009), it is likely that the observed
restoration of reward and withdrawal aversion associative memory by co-administration
of a calcineurin inhibitor may be a result of indirectly blocking downstream Cdk5,
although this question requires further investigation.

3.4.1

Conclusions

The present findings demonstrate that chronic opiate exposure and withdrawal alters both
the expression of the D3R in the BLA, and the function of the D3R in the context of
opiate associative reward and withdrawal aversion memories. Furthermore, chronic
opiate exposure and withdrawal induced functional adaptations in both Cdk5 and
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calcineurin, two signaling pathways closely linked to the functional properties of the
D3R. These findings add to a growing body of evidence that chronic opiate exposure
results in profound alterations to the expression and function of DA-D3R transmission
and associated downstream signaling pathways, and identifies a novel plasticity
mechanism within the BLA linked to both reward and withdrawal-aversion related
associative memory formation. The demonstration that the eﬀects of opiate exposure and
withdrawal on intra-BLA molecular memory mechanisms are reversible with targeted
pharmacological manipulations of the Cdk5/calcineurin signaling pathways adds to
growing evidence demonstrating the plastic nature of opiate-induced neuroadaptations
and the potential clinical significance of targeting opiate-related associative memory
formation as a potential treatment for persistent opiate-related addiction memories.
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Chapter 4

4

A TEMPORAL ANALYSIS OF OPIATE-INDUCED
ALTERATIONS TO INTRA-BLA SIGNALING
MOLECULES IMPLICATED IN THE FORMATION OF
ASSOCIATIVE DRUG MEMORIES
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4.1 INTRODUCTION
In the mammalian brain, regions associated with reward learning and memory are
profoundly altered by chronic exposure to drugs of abuse. The basolateral amygdala
(BLA) is the primary center for the processing of first-order associations between
affective drug states and contextual cues via dopaminergic signaling. Interestingly,
dopamine (DA) signaling is functionally altered by chronic opiate exposure such that the
processing of opiate-related memories transitions from the use of a D1-dependent to a
D2/D3-dependent mechanism between an opiate-naïve and an opiate-dependent and
withdrawal state (Lintas et al., 2011; Lyons et al., 2013; Rosen et al., 2017).
Recent evidence further suggests that downstream signaling targets related to the D1R
and D2/3R, also undergo changes in function and expression within the BLA following
chronic heroin exposure (Lyons et al., 2013; Rosen et al., 2015, 2017). Specifically,
extracellular signal-related kinase 1/2 (ERK1/2), Ca2+/calmodulin-dependent protein
kinase type II α isoform (CaMKIIα), calcineurin A (calcineurin), and cyclin-dependent
kinase 5 (Cdk5) have each been identified as molecular targets that are subject to opiateinduced neuroplastic alterations, particularly in the context of synaptic plasticity events
and drug-related associative memory formation (Mansuy et al., 1998; Ferrer-Alcón et al.,
2003; Biala et al., 2005; Gerdjikov and Beninger, 2005; Narita et al., 2005; Xie et al.,
2009; Baumgärtel and Mansuy, 2012; Lyons et al., 2013; Rosen et al., 2015).
Although the evidence of changes to DA signaling in mesocorticolimbic regions as a
result of opiate exposure is growing, there is little understanding of the temporal
dynamics of the molecular switching that occurs as a consequence of opiate addiction.
Understanding the time course of cellular and molecular alterations resulting from opiate
addiction is profoundly important from a clinical perspective. Opiate addiction is highly
resistant to extinction, and memories linked to the addiction process can remain latent for
years after abstinence, only to be unexpectedly triggered by exposure to associative cues
that reinstate opiate seeking compulsive behaviours. This has raised the question of
whether addiction is a permanent disorder.
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Thus, it is critical to assess the permanence of both molecular and behavioural changes
within mesocorticolimbic regions following chronic heroin exposure. Gao and colleagues
(2013) have found that DA transmission (via D1 and D2Rs) within the nucleus
accumbens shell region and caudate putamen is involved in opiate-seeking behaviour,
even after prolonged abstinence. However, there is little work that directly compares
intra-BLA DA signaling between opiate-dependent brains in acute withdrawal versus
those at various stages of opiate recovery.
Here, we address the temporal dynamics and permanence of alterations to intra-BLA DA
receptor signaling targets following the cessation of chronic heroin exposure. Using a
western blotting procedure, we examined the expression of intra-BLA ERK1/2,
CaMKIIα, calcineurin and Cdk5 at multiple time points, ranging from before the onset of
heroin withdrawal to 30 days following the cessation of heroin treatment.
We report that changes to signaling molecules within the BLA do not share a uniform
time course relative to latency from spontaneous heroin withdrawal. Interestingly,
particular signaling targets in heroin-treated animals appear to demonstrate peak change
relative to opiate-naïve animals at distinct time points. This suggests that protracted
opiate dependence may be a dynamic process with multiple phases, rather than a single
neurobiological switch. Furthermore, we report that specific signaling pathways may
represent the most promising targets for the treatment of long-term opiate addiction.

4.2 MATERIALS AND METHODS
4.2.1

Animals

All procedures were performed in accordance with the Canadian Council on Animal
Care and approved by the Western University Council on Animal Care. Male
Sprague-Dawley rats (350-400 g; Charles River) were used for all experiments.
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4.2.2

Drug treatments and Comparison of Opiate Exposure States

Experimental groups consisted of heroin- or vehicle-treated animals. For chronic opiate
exposure groups, rats were pre-treated with once-daily injections of 0.5 mg/kg heroin
(s.c.) (diacetyl-morphine, MacFarlane Smith; dissolved in physiological vehicle; pH
adjusted to 7.4) in their home cage for a total of 15 days. Non-dependent rats received
vehicle (saline) injections over the same time course, in place of heroin. This regimen
produces aversive motivational effects (conditioned place aversion) similar to those
produced by a 3-weeks of morphine administration (Bechara et al., 1995; Laviolette and
van der Kooy, 2004), thus indicating a state of potent opiate dependence. The 15-day
regimen also allows for results that are easily compared to previous work (Lyons et al.,
2013; Rosen et al., 2015)
Four time points were chosen for analysis, each labeled for the latency of analysis from
the final treatment injection and are summarised in Table 4.1. Although much research
has been conducted on the effects of chronic heroin on reward memory acquisition during
opiate dependence and withdrawal (Lintas et al., 2011; Lyons et al., 2013; Rosen et al.,
2015, 2017), it is unclear whether some observed effects are related to opiate dependence
or withdrawal specifically. Thus, we assessed tissue from animals in a state of opiate
dependence, but not withdrawal, 3 hr following the final heroin injection.
Previous work has demonstrated that a functional recovery of D1 signaling within the
BLA occurs following chronic heroin exposure after as little as 7 days following
cessation of heroin treatment (Lintas et al., 2011). We therefore included a 7d recovery
group in our analyses. The 14d and 30d recovery groups were included to assess two
long-term points of assessment. Thus, protein extractions occurred at four separate time
points, measured by their latency from the 15th daily injection: 3hr, 7d, 14d, 30d, with
labels outlined in Table 4.1.
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Time from final injection

Heroin-treated

Vehicle-treated

3 hours

H3hr

V3hr

7 days

H7d

V7d

14 days

H14d

V14d

30 days

H30d

H30d

Table 4.1 Summary of experimental group names

4.2.3

Western blot procedure

At each time point, n = 8 non-dependent and n = 8 chronically exposed animals were
sacrificed for tissue extraction. Upon sacrificing, animals’ brains were rapidly removed
and sectioned in order to obtain a micro-punch of the amygdala. Tissue samples were
manually homogenized with a Dounce homogenizer and protein was isolated using a
lysis buffer with a protease inhibitor (HaltTM protease and phosphatase inhibitor cocktail;
ThermoFisher). Following homogenization, samples were mixed with 2X Laemmli
loading buffer and heated to 95oC for 5 minutes prior to storage in a -80oC freezer.
For blotting, 12.5µg of protein from time yoked non-dependent and chronically exposed
animals were loaded in an alternating pattern onto 10 or 12% denaturing SDS-Page gels.
A BLUeye prestained protein ladder (FroggaBio) was loaded onto each gel in order to
confirm the molecular weight of proteins of interest. Gel electrophoresis was run for 1 h
at 125V in a Mini-PROTEAN 3 Western blot apparatus (Bio-Rad). Protein was then
transferred to a nitrocellulose membrane (Bio-Rad) via a Mini Trans-Blot Cell (Bio-Rad).
Membranes were stained with Ponceau S to ensure approximately equal protein volume
across lanes and to verify the integrity of the protein before probing.
Blots were then blocked with 2.5% non-fat dried milk (NFDM; Carnation) in TBS-T for
1 h at room temperature on a rocker. Blots were then incubated overnight with rocking at
4oC in a TBS-T solution containing the primary antibody of interest and either 2.5%
Bovine Serum Albumin Fraction V (Calbiochem) or 2.5% NFDM as recommended by
the manufacturer.
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Primary antibody dilutions were as follows: phosphorylated Cdk5 [Tyr 15] (pCdk5;
1:100; Santa Cruz Biotechnology), Cdk5 (1:200; Santa Cruz Biotechnology), Calcineurin
A (CnA; 1:100,000; Sigma-Aldrich) and α-tubulin (1:120,000; Sigma-Aldrich). All
secondary antibodies (Thermo Scientific) were used at a 1:10,000 dilution. Following
incubation with the primary antibody, blots were washed with TBST (3× each for 5 min).
Primary antibody dilutions are summarized in Table 4.2.
Blots were then incubated for 1h at room temperature with secondary antibodies
(IRDye® goat anti-rabbit, goat anti-mouse; each at 1:10,000; LI-COR Biosciences; Table
4.3). Membranes were then washed with TBST (3× each for 5 min) followed by TBS (5
min).

Target

Species

Dilution

Calcineurin A

Mouse

1:100,000

pCaMKIIα

Rabbit

1:1,000

CaMKIIα

Rabbit

1:2,000

pERK1/2

Rabbit

1:1,000

ERK1/2

Rabbit

1:2,000

pCdk5

Goat

1:200

Cdk5

Rabbit

1:200

α-tubulin

Mouse

1:1,000,000

α-tubulin

Rabbit

1:5,000

Table 4.2 Summary of primary antibodies used
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Antibody

Colour

Catalog #

Dilution

Donkey anti-rabbit

Green

926-32213

1:10,000

Donkey anti-goat

Green

926-32214

1:10,000

Donkey anti-mouse

Red

926-68072

1:10,000

Donkey anti-rabbit

Red

926-68073

1:10,000

Table 4.3 Summary of secondary antibodies used

4.2.4

Data Visualization and Analysis

Visualisation of protein levels was performed with the Odyssey Imaging System (LICOR Biosciences). Densitometry values for western blots were obtained with Kodak
digital analysis software. Outliers were identified using Chauvinet’s criteria, and
excluded from analysis. Main effects were analyzed with two-way analysis of
variance (ANOVA), and post hoc analyses were performed with Fisher’s least
significant difference (LSD) test where appropriate.

4.3 RESULTS
4.3.1

Chronic heroin exposure alters calcineurin expression during
acute dependence

Representative blots of calcineurin expression across all timepoints is presented in Fig.
4.1A. A comparison between heroin-treated and vehicle-treated animals revealed no
significant effect of treatment or time from final injection on the expression of
calcineurin (F(1,51) = 2.094, p = .154, F(3, 58) = 1.894, p = .142, respectively; see Fig.
4.1B). A trend towards significance was found for a time by group interaction F(3, 58) =
2.164, p = .104. Post-hoc analyses revealed that heroin-treated animals showed an
increase in calcineurin expression as compared to vehicle-treated animals 3 hours
following final treatment injection (p < .01). Animals in the H3hr group also displayed
significantly more calcineurin than animals in H7d, H14d and H30d (p’s < .05).
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Figure 4.1 Intra-BLA calcineurin expression following the cessation of chronic
heroin treatment
Chronic heroin exposure differentially affects the expression of calcineurin in the BLA in
a time-dependent manner. (A) Representative western blots for calcineurin expression
over time. (B) Densitometry analyses revealed time-dependent alterations to calcineurin
expression. ** p < .01, * p < .05.

4.3.2

Chronic heroin exposure does not alter CaMKIIα expression
in animals outside the withdrawal state

Previous reports of CaMKIIα expression in heroin-exposed animals showed a dramatic
downregulation in both pCaMKIIα and CaMKIIα 21 hours following cessation of heroin
treatment when animals are in a state of acute withdrawal (Lyons et al., 2013).
Interestingly, we did not observe any effects of heroin exposure when animals are not in a
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state of withdrawal (representative blots shown in Fig. 4.2A, C). Heroin-treated and
vehicle-treated animals showed no significant effect of heroin treatment or time from
final injection on the expression of pCaMKIIα (F(1,54) = 0.313, p = .578, F(3, 61) = 0.795, p
= .502, respectively). Additionally, no significant interaction between treatment and time
was observed F(3, 61) = 0.482, p = .696 (Fig. 4.2B).
Furthermore, a comparison between heroin-treated and vehicle-treated animals revealed
no significant effect of heroin treatment or time from final injection on the expression of
CaMKIIα (F(1,53) = 1.777, p = .188, F(3, 60) = 0.093, p = .963 respectively). Additionally,
no significant interaction between treatment and time was observed F(3, 60) = 0.258, p =
.855 (Fig. 4.2D).
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Figure 4.2 Intra-BLA CaMKIIα expression following the cessation of chronic heroin
treatment
Chronic heroin exposure does not alter the expression of CaMKIIα. (A) Representative
western blots for pCaMKIIα over time. (B) Densitometry analyses found no effect of
treatment or time on the expression of pCaMKIIα. (C) Representative western blots for
CaMKIIα over time. (D) Densitometry analyses found no effect of treatment or time on
the expression of CaMKIIα. (E) Densitometry analyses found no effect of treatment or
time on the ratio of phosphorylated to total CaMKIIα expression.

Finally, analysis revealed no significant effect of heroin treatment or time from final
injection on the ratio of phosphorylated to total CaMKIIα (F(1,51) = 2.99, p = .090, F(3, 58)
= 0.722, p = .544, respectively). No significant interaction between treatment and time
was observed F(3, 58) = 0.164, p = .920 (Fig 4.2E).
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4.3.3

ERK1 expression is altered by chronic heroin exposure

Representative pERK1 blots are presented in Fig. 4.3A. Western blot analysis revealed
no significant effect of treatment (F(1,54) = 0.591, p = .445), time (F(3, 61) = .690, p = .562)
or a group by time interaction (F(3, 61) = 1.574, p = .206) on the expression of pERK1.
Post-hoc analysis, however, revealed a significant decrease in pERK1 between H3hr and
H14d (p < .05; Fig 4.2B).
Furthermore, no significant effect of treatment or time on the expression of ERK1 (Fig.
4.3D) was found (F(1,51) = 2.078, p = .156, F(3, 58) = 0.174, p = .913, respectively).
Additionally, no significant treatment by time interaction was observed (F(3, 58) = 0.829, p
= .484; Fig 4.3E).
Analysis revealed no significant effect of time and no significant time by treatment
interaction on the ratio of phosphorylated to total ERK1 (F(3, 56) = 0.539, p = .658, F(3, 56)
= 0.942, p = .428, respectively; Fig. 4.3G). A significant treatment effect was observed
(F(1,49) = 4.561, p = .038). Post-hoc analysis revealed that animals in the H14d group
showed a significantly lower p:tERK1 ratio than V14d (p < .05). Animals in the H14d
group also showed a significantly lower p:tERK1 ratio than H3hr (p < .05).
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Figure 4.3 Intra-BLA ERK1/2 expression following cessation of chronic heroin treatment
Chronic heroin exposure differentially affects the expression of ERK1/2 in the BLA in a
time-dependent manner. (A) Representative western blots for pERK1/2 over time. (B)
Densitometry analyses revealed a decrease in pERK1 expression in heroin-treated
animals between the 3 hr and 14 d time points. (C) Densitometry analyses revealed timedependent alterations to pERK2 expression. (D) Representative western blots for
pERK1/2 over time. (E) Densitometry analyses found no effect of treatment or time on
the expression of ERK1. (F) Densitometry analyses found a decrease in ERK2 expression
in heroin-treated animals from the 3 hr and 7 d time points to the 30 d time point. (G)
Densitometry analysis revealed a decrease in the p:tERK1 ratio between heroin-treated
and saline-treated animals at the 14 d time point. Heroin-treated animals also had a
significantly lower p:tERK1 ratio relative to heroin-treated animals at the 3 hr time point.
(H) Densitometry analysis revealed both time- and treatment-dependent effects on the
p:tERK2 ratio. ** p < .01, * p < .05.

4.3.4

ERK2 expression is altered by chronic heroin exposure

Representative pERK2 blots are presented in Fig. 4.3A. A significant effect of time and a
significant time by treatment interaction were found on the expression of pERK2 (F(3, 60)
= 5.851, p = .002, F(3, 60) = 3.617, p = .019, respectively; Fig. 4.3C). Post-hoc analysis
revealed that at 3 hours after final treatment injection, H3hr animals expressed
significantly more pERK2 than V3hr animals (p < .05). At 7d, H7d animals expressed
significantly less pERK2 than V7d animals (p < .05). H3hr animals expressed
significantly more pERK2 than H7d (p < .01), H14d p < .01) and H30d (p < .05). H30d
expressed significantly more pERK2 than H14d (p < .05).
Analysis showed no significant effect of treatment, or a significant treatment by time
interaction (F(1,52) = 1.748, p = .192, F(3, 59) = 1.135, p = .484, respectively) on the
expression of ERK2 (representative blots shown in Fig 4.2D). A significant effect of time
was observed (F(3, 59) = 4.360, p = .008; Fig. 4.3F). Animals in H30d expressed
significantly less ERK2 than animals in H3hr (p < .05) and H7d (p < .01).
There was no observed effect of treatment on the phosphorylated to total ERK2
expression (F(1,49) = 1.730, p = .195; Fig 4.3H). A significant effect of time (F(3, 56) =
6.956, p = .001) and a trending significant time by treatment interaction (F(3, 56) = 2.488, p
= .071) were observed. Post-hoc analyses revealed that H7d expressed a significantly
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smaller p:tERK2 ratio than V7d (p < .05). H3hr had a significantly bigger p:tERK2 ratio
than H7d (p < .01) and H14d (p < .01). Furthermore, H30d had a significantly greater
p:tERK2 ratio than H7d (p < .01) and H14d (p < .01).

4.3.5

Cdk5 is altered by chronic heroin exposure following
prolonged abstinence

Representative pCdk5 blots are shown in Fig 4.4A. Analysis revealed no significant main
effect of treatment on the expression of pCdk5 (F(1,54) = 0.099, p = .754; Fig 4.4B). A
trend toward a significant effect of time on the expression of pCdk5 was observed (F(3, 61)
= 2.272, p = .091). A significant treatment by time interaction was observed (F(3, 61) =
4.367, p = .008). H30d animals expressed significantly greater levels of pCdk5 than V30d
animals (p < .01) Animals at H30d also expressed significantly higher levels of pCdk5
than H3hr (p < .01), H7d (p < .05) and H14d (p < .01).
Representative Cdk5 blots are shown in Fig 4.4C. A trending effect of both treatment
(F(1,55) = 3.684, p = .060) and time following final treatment injection (F(3, 62) = 2.660, p =
.057) was observed. No significant treatment by time interaction was observed (F(3, 62) =
2.038, p = .119). Animals in the H7d group expressed significantly less Cdk5 than V7d
animals (p < .05). Animals in the H3hr group expressed significantly more Cdk5 than the
H7d group (p < .05), the H14d group (p < .01) and the H30d group (p < .05).
Heroin treatment had a significant effect on the ratio of phosphorylated to total Cdk5
(F(1,53) = 7.494, p = .008; Fig 4.4E). Time from final treatment injection, however, had no
effect on the phosphorylated:total Cdk5 ratio (F(3, 60) = 1.663, p = .186; Fig 4.4D). The
treatment by time interaction was trending towards significant (F(3, 60) = 2.511, p = .069).
Post-hoc analysis revealed that animals in H14d had a significantly higher p:tCdk5 ratio
than V14d (p < .01), and that H30d showed a significantly greater p:tCdk5 ratio than
V30d (p < .05). H3hr had a significantly lower p:tCdk5 ratio than both H14d and H30d
(p’s < .01).
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Figure 4.4 Intra-BLA Cdk5 expression following cessation of chronic heroin
treatment
Chronic heroin exposure differentially affects the expression of Cdk5. (A) Representative
western blots for pCdk5 over time. (B) Densitometry analysis revealed both time- and
treatment-dependent effects on pCdk5. (C) Representative western blots for Cdk5 over
time. (D) Densitometry analysis revealed both time- and treatment-dependent effects on
Cdk5. (E) Densitometry analysis revealed both time- and treatment-dependent effects on
the p:tCdk5 ratio. ** p < .01, * p < .05.

4.3.6

Summary of Results

The above results demonstrate a complex pattern of heroin-induced alterations to the
expression of our proteins of interested based on time elapsed from the final heroin
injection and signaling molecule. By taking into account heroin-induced changes to
signaling molecules that have been previously observed 21 hrs following the cessation of
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heroin treatment (i.e. during a state of opiate dependence and withdrawal; Lyons et al.,
2013; Rosen et al., 2015; Rosen, Rushlow, & Laviolette, 2017), it appears that the
individual signaling molecules demonstrate peak alterations at different time points.
In particular, calcineurin shows the most profound changes at early time points, followed
by CaMKIIα during opiate dependence and withdrawal. At later time boys (i.e. 7 d after
the cessation of heroin treatment and beyond), the most notable heroin-induced
alterations to the expression of signaling molecules are seen in ERK1/2 and Cdk5. A
summary of this pattern of results is outlined in Table 4.4

Table 4.4 Summary of results
Summary of heroin-induced changes to molecular signaling molecules as a function of
time elapsed from the cessation of heroin treatment. Double arrows represent statistical
significance (p < .05), and single arrows indicate a statistical trend (p < .1). Results for
the 21 hr time point were published previously (Lyons et al., 2013; Rosen et al., 2015,
2017) and included here for ease of comparison.
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4.4 DISCUSSION
The BLA is the primary brain region responsible for processing first-order associative
drug memories via DAergic signaling (Guo et al., 2008; Lintas et al., 2011; Luo et al.,
2013; Lyons et al., 2013). Anatomically, the BLA serves as a critical nexus point in the
opiate addiction process as it receives inputs from other addiction-related brain regions,
such as the VTA DAergic efferents, inputs from the PFC, and inputs from the
hippocampus signaling contextually relevant information (Pitkänen et al., 2000; Ford et
al., 2006). Given the functional importance of VTA DAergic inputs to the BLA, it is not
surprising that chronic exposure to opiates has been shown to alter the expression of DA
receptors and downstream signaling molecules that are responsible for the formation of
these memories. Furthermore, these alterations have been demonstrated to affect opiaterelated reward and aversion memories (Lyons et al., 2013; Rosen et al., 2015, 2017). The
time course of these changes, however, remains poorly understood. Whether chronic
opiate exposure results in a single major neuronal event or a longer-term series of
changes has not been previously investigated. Here, we report that chronic heroin
exposure results in differential, time-dependent alterations to signaling targets
downstream of DA receptors. Interestingly, the profile of changes to these signaling
targets is not uniform over time. Rather, it appears that specific signaling molecules
demonstrate their most profound changes in expression over unique timelines.

4.4.1

Calcineurin

The expression of calcineurin is increased in heroin-treated animals only 3 hr following
the cessation of heroin treatment, and returns to control levels by the 7 d timepoint.
Previous reports have found that chronic heroin exposure results in a dramatic increase in
intra-BLA calcineurin expression (Rosen et al., 2017). The effects found here are
relatively modest when compared to our previous study of calcineurin in the BLA 21
hours following heroin exposure (Rosen et al., 2017). It is therefore possible that chronic
heroin results only in shorter-term changes to calcineurin. This may reflect involvement
of calcineurin in early acquisition of associative opiate memories, and is consistent with
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reports that calcineurin is critical for transitioning memory traces from short- to longterm storage (Mansuy et al., 1998).

4.4.2

CaMKIIα

In this study, heroin-treated animals demonstrated no change in the expression of either
phosphorylated or total CaMKIIα expression relative to control animals. These results are
in stark contrast to previous reports that chronic heroin exposure leads to a drastic
downregulation of CaMKIIα (Lyons et al., 2013). This suggests that the previously
observed opiate-induced changes to CaMKIIα may be more attributable to opiate
withdrawal, rather than dependence. Previous studies have found that the formation of
opiate reward memories is blocked by both intra-BLA and intra-PFC CaMKIIα
antagonism when the CaMKIIα antagonist AIP is applied when animals are in a state of
opiate withdrawal (Lyons et al., 2013; Rosen et al., 2015). Whether the restoration of
CaMKIIα expression seen here may render opiate associative memory formation
insensitive to AIP administration when applied at later time points (i.e. 7 d and beyond) is
an interesting question for future study. For instance, previous work has shown that the
switch between intra-BLA D1 and D2 receptor function that is observed following
chronic opiate exposure is reversed following a 7-day recovery period (Lintas et al.,
2011). It is also possible that opiate-induced behavioural changes to CaMKIIα during the
withdrawal process may gate further changes related to opiate associative memory
formation at later time points.

4.4.3

ERK1/2

Our investigation into heroin-induced changes to ERK expression revealed no difference
in the expression of intra-BLA pERK1 or ERK1 between heroin- and saline- treated
animals. This is in contrast to previous reports that ERK1 function and expression are
altered by chronic heroin treatment when animals are observed 21 hr following the
cessation of heroin treatment (Lyons et al., 2013; Rosen et al., 2015). However, we did
observe that reductions in ERK1 activation in heroin animals between the 3 hr and 14 d
timepoints results in an alteration in the ratio of phosphorylated to total ERK1 between
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heroin- and saline-treated animals. It is unknown whether the decrease in the p:tERK1
ratio at the 14 d timepoint would result in any functional changes to opiate associative
memory formation, but it is a valuable question for future study.
In contrast to ERK1 expression, heroin-induced changes to ERK2 expression are more
profound and complex. The expression of pERK2 in heroin-treated animals is
significantly higher than saline-treated controls at the 3 hr timepoint, but drops relative to
saline controls by the 7 d timepoint before recovering to control levels. The differences in
p:tERK2 ratio between heroin- and saline-treated animals follows a similar pattern,
showing a decrease at longer-term time points. This is consistent with previous reports of
a lowered ratio of phosphorylated to total ERK1/2 in morphine-dependent rats (RamosMiguel et al., 2011).

The greater changes in ERK2 expression as a result of heroin exposure are inconsistent
with reports that ERK1 and ERK2 are similarly affected by long-term heroin treatment at
the 21 hr timepoint (Lyons et al., 2013). However, there is evidence that chronic opiate
exposure has differential effects on the expression of ERK1 and ERK2 within the mPFC
(Rosen et al., 2015). The behavioural implications for distinct patterns of these results in
these two molecules in unclear, as the functional difference between ERK1 and ERK2 is
not well understood (Kyosseva, 2004). There is evidence that ERK1 knockout mice are
viable, but mice lacking ERK2 are not (Pouysségur et al., 2002), suggesting that
implications of large changes to ERK2, but not necessarily ERK1, may warrant further
investigation.

4.4.4

Cdk5

Our Cdk5 analyses showed that an increase in pCdk5 relative to saline control animals is
only observed at the 30 d time period, indicating that long-term changes to Cdk5 may
encode previous history of heroin exposure. This is accompanied by decreases in total
Cdk5, and an increase in the p:tCdk5 ratio at later (14 d, 30 d) time points. This suggests
that Cdk5 may be involved in the longer-term neuroadaptations that result as a
consequence of heroin exposure, and could even be a candidate target for understanding
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why previously opiate-exposed animals and humans alike remain prone to relapse long
after drug dependence has passed. (Li et al., 2008; Pickens et al., 2011). This finding is in
accordance with other studies that have suggested that sustained morphine exposure
results in Cdk5-dependent long-term neuroplastic effects in mesolimbic regions (RamosMiguel and García-Sevilla, 2012). Interestingly, Chen et al. (2016) have suggested that
alterations to Cdk5 signaling may reflect a compensatory mechanism that limits further
heroin-seeking. Combined with the results presented here, Cdk5 appears to be a
promising target in understanding the long-term neuroplastic adaptations that occur as a
result of heroin addiction.

4.4.5

Summary and Future Directions

All together, the pattern of results in this study suggests that addictive states are more
likely to result in a cascade of neurobiological adaptations over time, rather than one,
discrete event. However, one major outstanding question related to the results outlined
here is the effect of these molecular changes on drug-related memories and behaviours.
Previous investigations into the effects of heroin on intra-BLA DA receptors and their
downstream targets have found not only changes in expression, but alterations to their
role in opiate reward and aversion memory acquisition (Lintas et al., 2011; Gholizadeh et
al., 2013; Lyons et al., 2013; Rosen et al., 2017).
Furthermore, previous reports have investigated the role of interconnected
mesocorticolimbic regions in the acquisition, maintenance and retrieval of opiate-related
memories. The PFC, VTA and nucleus accumbens have all demonstrated functional
alterations to DAergic signaling following chronic heroin exposure (Laviolette et al.,
2002; Lane et al., 2008; Tan et al., 2014; Rosen et al., 2015). Understanding the shifting
patterns of expression and function in memory-related molecules as a function of opiate
exposure would thus be of value in these regions, as well
Understanding the time-dependence of these changes is also critical for future
investigation. For instance, the PFC has previously shown a complementary pattern of
molecular changes following chronic opiate exposure relative to the BLA (Rosen et al.,

123

2015). It would be interesting to assess whether the pattern of these changes relative to
the BLA are expressed in the opposite direction at time points other than during acute
opiate withdrawal.
To gain a better understanding of the cascading alterations to reward memory molecules
as a result of chronic heroin exposure, there are a number of potentially interesting
molecular targets to investigate. For instance, dopamine- and cAMP-regulated
phosphoprotein, Mr 32 kDa (DARPP-32; also known as PPP1R1B) mediates neuronal
activity of many drugs of abuse, including opioids (reviewed in Svenningsson et al.,
2005). DARPP-32 can be found colocalized with DA receptors in the rat cortex and
striatum (Rajput et al., 2009), and its activity is affected by opioid receptor activation via
DAergic mechanisms (Lindskog et al., 1999). Furthermore, DARPP-32 is directly
regulated by molecules involved in memory formation, including Cdk5 (Greengard et al.,
1999) and calcineurin (Chiocco et al., 2010).
Given its role as a Cdk5 activator and mediator of MEK/ERK, PP1 and calcineurin
signaling with respect to long-term plasticity events, p25 is also a promising target of
future study into the effects of chronic opiate exposure (Sharma et al., 2002; Takahashi et
al., 2005; Seo et al., 2014). Indeed, some studies have already found p25 expression to be
altered by chronic morphine administration, and may be involved in long-term
neuroplastic alterations resulting from opiate exposure (Ramos-Miguel and GarcíaSevilla, 2012).
Perhaps one of the most exciting implications of this study is that opiate addiction may
not be, as often believed, a disease that results in permanent, untreatable neurobiological
changes (see Self, 2004; Satel and Lilienfeld, 2014). Furthermore, this may address
critical issues surrounding traditional treatments for opiate addiction (i.e. naloxone,
methadone maintenance) that are aimed at preventing the aversive effects of withdrawal
to reduce compulsive drug seeking, but have limited long-term efficacy (Petitjean et al.,
2001; De Maeyer et al., 2011). Perhaps the results outlined here may guide more targeted
treatment for the recovery from opiate addiction at various stages of the disease.
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5

GENERAL DISCUSSION
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5.1 SUMMARY OF RESULTS AND CONCLUSIONS
5.1.1

Chronic opiate exposure results in a functional switch of D2CaMKIIa signaling within the BLA-mPFC circuit

Following the discovery of an opiate exposure-dependent molecular switch between the
role of D1 vs D2 signaling in the BLA in the formation of opiate reward memories
(Lintas et al., 2011), we aimed to extend this work into other regions within the
mesocorticolimbic circuitry. Given its bidirectional connections with the BLA, the mPFC
was a prime target for expanding our investigation.
We found that within the mPFC, opiate exposure state predicts a similar molecular switch
between D1 and D2 function in the acquisition of opiate reward memories. Animals in an
opiate naïve state required D2 activity to form a conditioned place preference to a
morphine environment, but D2 antagonism in opiate dependent and withdrawn animals
did not affect the formation of an opiate reward memory. Like previous reports of
intracellular DA target signaling in a similar paradigm (Lyons et al., 2013), the role of
CaMKIIα is similarly reversed between opiate exposure states, with antagonism of intraPFC CaMKIIα signaling resulting in the block of opiate memory formation in the opiate
naïve state, but not the chronically exposed/withdrawn state. Interestingly, the intra-PFC
switch we observed in Chapter 2 is functionally opposite to the one found previously in
the BLA (Lintas et al., 2011; Lyons et al., 2013).
Chapter 2 further explored the role of an integrated BLA-mPFC circuit in the acquisition
of opiate reward memory. We found that functional dissociation of the BLA and mPFC
resulted in a block of opiate reward memory formation.
Together, these results not only extend evidence for a functional molecular switch in the
context of reward memory formation following the transition to opiate dependence, but
also further underscore the importance of the BLA-mPFC circuit in these processes.
Furthermore, we found that the magnitude of observed changes to the PFC following
what was previously reported in the BLA as a result of chronic opiate exposure (Lyons et
al., 2013), was more modest. As a result, we identified the BLA as a more promising
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target region for further understanding opiate-exposure-induced changes to the molecular
substrates underlying first-order associative opiate memory formation (Chapter 3).

5.1.2

Chronic opiate exposure alters intra-BLA D3Cdk5/calcineurin signaling in both reward and aversion
memory formation

Given the magnitude of both molecular and behavioural changes seen in BLA vs. mPFC
in Chapter 3, we shifted focus towards better understanding the extent of the molecular
memory switch that occurs within the BLA as a result of opiate exposure. Previous
studies investigating the switch in D1/D2 function and expression as a consequence of
opiate exposure did not explore the role of distinct D2 subtypes (Lintas et al., 2011;
Lyons et al., 2013; Rosen et al., 2015). The D3 receptor has become a promising target in
understanding addiction-induced neuroplastic changes, thus we decided to explore how
D3 signaling in the BLA may contribute to the acquisition of both opiate reward and
withdrawal aversion memory formation following chronic opiate exposure.
We found that opiate reward memory formation is insensitive to D3 blockade in
previously opiate naïve animals. In opiate-dependent animals, however, the formation of
both opiate reward and withdrawal aversion memories were dependent upon intra-BLA
D3 receptor signaling. This functional switch was accompanied by increases in Cdk5 and
calcineurin expression, and a decrease in D3 expression. By inhibiting the increases in
Cdk5 and calcineurin, we were able to return intra-BLA reward and aversion memory
formation back to a D3-independent state in opiate dependent animals.
These findings add to the growing body of evidence that chronic heroin exposure results
in alterations to the function and expression of intra-BLA DA transmission in the context
of drug-related memory formation. The demonstration that the observed effects could be
functionally reversed by restoring intracellular signaling targets back to an opiate naïve
phenotype highlights the plastic nature of opiate-induced effects on the
mesocorticolimbic system. Thus, these findings demonstrate the potential clinical
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significance of targeting associative opiate memory formation for treating pervasive
opiate addiction.

5.1.3

Chronic opiate exposure alters the expression of intracellular
targets underlying drug memory formation in a timedependent manner

Following the completion of Chapter 3, we began to uncover the extent of the DA
receptors and targets that are affected by chronic opiate exposure. Until this point,
however, all of our analyses had been performed while animals were in a state of opiate
dependence and withdrawal (Rosen et al., 2015, 2017). This left a number of questions
unanswered in regards to the time course of opiate-induced neuroplastic changes to the
BLA. Specifically, 1) which of the changes observed to date have been a function of
opiate dependence and which are a result of the acute withdrawal state and 2) what is the
permanence of these changes?
Thus, we examined the expression of DA receptor targets that we had previously found to
be altered by chronic heroin exposure. We probed for changes 3 hours following the
cessation of chronic heroin administration (i.e. when animals were in a state of opiate
dependence, but not withdrawal), as well as 7 days, 14 days and 30 days following the
cessation of chronic heroin treatment.
We identified time-dependent changes in the expression of intra-BLA calcineurin,
ERK1/2 and Cdk5. Specifically, the expression of calcineurin appeared to be altered only
in a state of acute heroin dependence, and returned to baseline levels beyond 7 days
following the cessation of heroin treatment. The expression of ERK1/2 appeared to be
affected at both the short and longer-term time points following chronic heroin cessation,
but also returned to normal near 30 days after chronic heroin treatment. Interestingly, the
maximal changes to Cdk5 expression were observed 14 days and 30 days following the
cessation of chronic heroin exposure, suggesting that Cdk5 could be involved in the
persistence of opiate addiction long after opiate use has stopped.
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We did not identify any changes to CaMKIIα expression at the time points examined in
this chapter, suggesting that the changes observed previously (Lyons et al., 2013; Rosen
et al., 2015) were indeed a result of acute withdrawal. Given that CaMKIIα antagonism
has still been shown to result in the block of associative opiate memory formation in the
drug-free state, this suggests that a lack of alteration to CaMKIIα at the later time points
may not in fact be indicative of a lack of behavioural effect, but this hypothesis will
require further study.

5.2 LIMITATIONS
As outlined in Chapter 1, the mesocorticolimbic system is a complex, interconnected
circuit of multiple brain regions. When studying such complex systems, one must
consider the relationship of reciprocal connections in addition to synergistic effects of
multiple neurotransmitters. For instance, the role of glutamatergic signaling within the
mesocorticolimbic system is well documented (Fields and Margolis, 2015). Not only has
glutamate been implicated in the development of opiate dependence (Siggins et al., 2003;
Martin et al., 2004), alterations to D1 and D2 receptors have been found to influence the
function of glutamatergic receptors, particularly in the context of synaptic strengthening
(Lane et al., 2008; Madhavan et al., 2013). Ultimately, a more complete view of the
mechanisms underlying drug memory processing will require a thorough investigation
into dynamics between neurotransmitter systems.
Similarly, the work outlined in this thesis has provided only a rudimentary analysis of the
intracellular mechanisms involved in opiate memory formation. Future work will be
required to uncover the complex interplay of intracellular signaling substrates in the
context of opiate associative memory processing. For instance, the ERK1/2 signaling
pathway is linked to more than just downstream D1 activity. Girault and colleagues
(2007) have proposed that the role of ERK1/2 may be to act as an integration hub of DA
and glutamate signals within the striatum, and that its role in processing drug-related
memories could indeed be widespread throughout the limbic system, and recruit multiple
neurotransmitter systems (Valjent and Pascoli, 2005; Girault et al., 2007; Philibin et al.,
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2011; Zamora-Martinez and Edwards, 2014). For instance, in the context of memory
formation, there is evidence that both ERK1/2 and CaMKIIα may be regulated by
serotonin signaling (Cammarota et al., 2008). DARPP-32 has also been proposed as an
integrator of signals converging at DAergic neurons via a variety of neurotransmitters
and neuromodulators, including glutamate (Svenningsson et al., 2004; Fernandez et al.,
2006), thus representing another viable target for studying the convergence of multiple
transmitter systems.
Furthermore, DA receptors regulate multiple signaling pathways not explored in this
thesis that have been studied in relation to addiction processes and could also be critical
for gaining a complete understanding of drug memory processing. Some of these targets
include the Akt-GSK3β-mTORC1 pathway and β-arrestin signaling (Kim et al., 2005;
Rozenfeld and Devi, 2007; Beaulieu and Gainetdinov, 2011; Salles et al., 2013; Miller et
al., 2014).
Broadly speaking, there are some inherent limitations to the above studies that need to be
considered when extending this work to a clinical research. By not using a selfadministration model of opiate addiction, we cannot relate the current findings to drug
memory formation in users that actively seek out drugs, nor can we shed light on how
opiate associative memories relate directly to the persistence of drug use despite adverse
consequences. For instance, chronic stress has been identified as a characteristic shared
by many addicts (Kreek and Levran, 2012). Stress in itself has been found to have effects
on habit-forming and decision making (Dias-Ferreira et al., 2009).
Evidently, opiate addiction is a complex disorder that does not exist in isolation of
psychosocial factors, and future work that can more closely tie basic research of reward
circuitry to the understanding of whole individuals living with a disorder would be of
immense value to developing an effective treatment for opiate addiction.
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5.3 FUTURE DIRECTIONS
As outlined in Chapter 1, the BLA-mPFC link is just one of many within the highly
interconnected mesocorticolimbic system. Further extending the work outlined in this
thesis to the greater mesocorticolimbic circuitry could help us to better understand the
behavioural significance of opiate associative memory processing. For example,
examinations of opiate-induced changed to NAc processing could help us to evaluate the
neurobiological underpinnings for how individuals act on cravings. As a primary brain
structure underlying memory formation, future studies of hippocampal activity in drugrelated memory processing would also be of value.
As discussed in Chapter 4, many questions remain about the behavioural significance of
long-term, opiate-induced alterations to intracellular DA signaling targets. In particular, it
would be interesting to evaluate the involvement of these long-term changes in the
incubation of drug craving. Both humans and rodents demonstrate a time-dependent
increase in cue-induced drug seeking following withdrawal from opiates, cocaine and
alcohol (Pickens et al., 2011). Whether some of the changes observed in Chapter 4
underlie this phenomenon is a potentially interesting area for future investigation.
The investigations of opiate-induced alterations to associative memory formation in this
thesis were focused exclusively on changes to the neurobiological substrates underlying
memory acquisition. Indeed, memory processing is complex and multi-faceted. A more
complete picture of how opiate exposure results in alterations to memory processing will
require examination of the consolidation, recall and extinction of associative memories,
as well. It would be particularly interesting to directly study the resistance of opiaterelated memories to extinction in the context of guiding the development of addiction
treatments (Everitt, 2014). Along these lines, studies of synaptic-level learning in opiate
related memory processing would also be necessary. Long-term potentiation and longterm depression are commonly studied mechanisms of learning and memory, and have
been identified as candidate mechanisms for understanding opiate-induced disruptions in
neural circuitry (Hyman and Malenka, 2001).
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Certainly, there are many compelling research questions to pursue in both basic and
clinical research on opiate addiction. Ultimately, it will be the convergence of many
techniques and approaches that will best guide the development of more effective
treatments and/or pharmacotherapies for addictive disorders. In this thesis, my integrative
research projects have revealed a series of novel molecular adaptations within the BLAmPFC circuitry related not only to how the brain physically adapts during the process of
opiate dependence, addiction and withdrawal, but how these neuroadaptations are
functionally linked to learning and memory processing and their associated behavioural
outcomes. The mechanistic role of these neuroadaptations in the context of processing
opiate-related addiction memories underscores not only the complexity of
neurophysiological and psychological underpinnings associated with opiate addiction, but
also the importance of taking an integrative approach to developing more effective
approaches to addiction treatment.
For example, most current pharmacotherapies for opiate dependence (e.g. methadone
therapy, naloxone and buprenorphine) primarily serve to target the underlying
pharmacological substrates required for maintaining opiate-related euphoria and/or
preventing the negative physiological and psychological effects of opiate withdrawal.
Nevertheless, evidence from my research highlights the importance of targeting specific
receptor systems and their downstream molecular signaling targets in order to block
and/or prevent the formation of opiate-related reward or withdrawal-related associative
memories, and how these interventions can lead to improved behavioural outcomes.
Thus, combining and integrating research and treatment modalities that target both
opiate-induced molecular adaptations in brain pathways such as the BLA-mPFC circuit
as well as the psychological underpinnings of opiate-related memory formation (e.g.
cognitive behavioural therapies), might ultimately serve as the most effective strategy for
combatting the devastation of the opioid epidemic.
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